Therapeutic nucleic acids and methods of use thereof
Isolated piRNAs from iPSC-EVs provide a cell-free therapeutic solution for ischemic cardiac muscle injury by modulating macrophage behavior and reducing inflammation and fibrosis, effectively promoting cardiac repair.
Patent Information
- Application Number
- PCT/US2026/028210
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-16
- Filing Date
- 2026-05-14
- Publication Date
- 2026-11-19
AI Technical Summary
Current treatments for ischemic cardiac muscle injury and associated inflammation and fibrosis, such as myocardial infarction, lack effective cell-free therapeutic options that can modulate inflammatory signaling and promote tissue repair without causing arrhythmias.
Administration of isolated nucleic acids, particularly piRNAs derived from induced pluripotent stem cell extracellular vesicles (iPSC-EVs), which modulate macrophage behavior and reduce inflammation and fibrosis by delivering therapeutic RNA sequences.
The iPSC-EV-derived piRNAs effectively reduce myocardial injury and promote cardiac repair by suppressing inflammatory cytokines and promoting a reparative microenvironment, offering a cell-free therapeutic approach comparable to stem cell therapy without arrhythmia risks.
Smart Images

Figure US2026028210_19112026_PF_FP_ABST
Abstract
Description
CSMC.028WO PATENTTHERAPEUTIC NUCLEIC ACIDS AND METHODS OF USE THEREOFREFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No.63 / 807367, filed May 16, 2025, the disclosure of which is hereby incorporated by reference in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED R&D
[0002] This invention was made with government support under Grant No. R01 HL 155346, awarded by the National Institutes of Health. The Government has certain rights in the invention.REFERENCE TO SEQUENCE LISTING
[0003] The present application is being filed along with a Sequence Listing XML in electronic format. The Sequence Listing XML is provided as a file entitled CSMC028WOSequenceListing.xml, created May 8, 2026, which is 32,519 bytes in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.BACKGROUND
[0004] The present disclosure generally relates to therapeutic nucleic acids derived from non-coding RNA (such as PlWI-interacting RNA (piRNA)) found in extracellular vesicles of induced pluripotent stem cells (iPSC-EV) and uses thereof to treat ischemic cardiac muscle injury and / or other diseases.SUMMARY
[0005] Provided herein is a method of treating a condition associated with inflammation and / or fibrosis, comprising administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3 ’ (SEQ ID NO: 1) or a sequence having no more than 3 substitutions thereto, wherein the nucleic acid is RNA, wherein the nucleic acid is atmost 35 nucleotides long, optionally wherein the nucleic acid is, or is about 25 nucleotides long. Also provided is a method of treating a condition associated with inflammation and / or fibrosis, comprising administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10) or a sequence having no more than 3 substitutions thereto, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is, or is about 25 nucleotides long.
[0006] Also provided herein is an extracellular vesicle (EV)-free method of treating a condition associated with inflammation and / or fibrosis, comprising administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a composition comprising: a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of a PlWI-interacting RNA (piRNA) in EVs from induced pluripotent stem cells (iPSC-EVs), or a sequence having (i) no more than 3 substitutions thereto, and / or (ii) a truncation of no more than 10 nucleotides thereof, wherein the nucleic acid is RNA, and wherein the nucleic acid is at most 35 nucleotides long; and a pharmaceutically acceptable excipient, wherein the composition is an EV-free composition, optionally wherein the piRNA is enriched in the iPSC-EVs.
[0007] Provided herein is a method of immunomodulation, comprising contacting an effective amount of an isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1) with a population of macrophages, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long. Also provided is a method of immunomodulation, comprising contacting an effective amount of an isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10) with a population of macrophages, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is, or is about 25 nucleotides long.
[0008] Provided herein is an isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionallywherein the nucleic acid is 25 nucleotides long. Further provided is an isolated nucleic acid comprising a nucleotide sequence of: 5’-SGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 32), wherein S is G or C, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long. Also provided is an isolated nucleic acid comprising a nucleotide sequence at least 95% identical to 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long. Further provided is an isolated nucleic acid comprising a nucleotide sequence at least 95% identical to 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10), wherein the nucleic acid is RNA, wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long.
[0009] Provided herein is an isolated nucleic acid comprising one of the following nucleotide sequences, or a sequence at least 95% identical to: (a) 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:1), wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long; (b) 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10), wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 22 nucleotides long; (c) 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11), wherein the isolated nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long; or (d) 5’-CGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 12), wherein the isolated nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long.
[0010] Also provided is a kit comprising: any one of the isolated nucleic acids of the present disclosure; and a pharmaceutically acceptable excipient.
[0011] Provided herein is a method of identifying candidate therapeutic nucleic acids, comprising: obtaining sequencing data of a plurality of nucleic acids from therapeutic extracellular vesicles (EV); identifying a candidate therapeutic nucleic acid based on: (a) an enrichment analysis of the sequencing data that has been annotated relative to a reference sequencing data of a plurality of nucleic acids from non-therapeutic EV, wherein the reference sequencing data has been annotated, wherein the enrichment analysis identifies a first sequence motif that is enriched in the sequencing data; and (b) a sequence-based quantification ofabundance of the sequencing data that has not been annotated, wherein the sequence-based quantification identifies a second sequence motif that is enriched in the sequencing data, wherein a sequence homology between the first sequence motif and the second sequence motif identifies a candidate therapeutic nucleic acid, optionally wherein the annotated sequencing data comprises annotation for one or more of piRNA, miRNA, and tRNA.BRIEF DESCRIPTION OF THE DRAWINGS
[0012] FIG. 1A is a table showing the source information of two different donor cell lines of the induced pluripotent stem cells (iPSCs)
[0013] FIG. IB is a collection of immunofluorescent images showing pluripotency markers in two iPSC cell lines.
[0014] FIGs. 2A-2C show the characterization of induced pluripotent stem cells extracellular vesicles (iPSC-EVs) from two donors.
[0015] FIG. 3A shows the cytokine array analysis of proteins released by macrophages treated with EVs or vehicle.
[0016] FIGs. 3B-3G show the quantitative analysis of major cytokines that were regulated by EV treatment.
[0017] FIG. 4A is a schematic showing the timeline of a mouse ischemia / reperfusion (ER) model.
[0018] FIG. 4B shows the representative images from TTC staining showing the infarct area in mice heart after vehicle or EV injection.
[0019] FIG. 4C shows the quantitative analysis of infarct area.
[0020] FIG. 4D shows quantification of cTNI level in mouse serum.
[0021] FIG. 5 shows the distribution of small RNA species in the EVs from two iPSC cell lines.
[0022] FIG. 6A shows the effect of iPSC-EVs in promotion of macrophages in mice post myocardial infarction using immunostaining of cardiac tissues for CD68.
[0023] FIG. 6B shows the effect of iPSC-EVs in promotion of macrophages in mice post myocardial infarction on CD68+ cell counts quantitatively.
[0024] FIG. 7A shows the effect of iPSC-EVs in modulating macrophage polarization in mice post myocardial infarction using immunostaining of cardiac tissues for iNOS.
[0025] FIG. 7B shows the effect of iPSC-EVs in modulating macrophage polarization in mice post myocardial infarction on iNOS+ cell counts quantitatively.
[0026] FIG. 7C shows the effect of iPSC-EVs in modulating macrophage polarization in mice post myocardial infarction using immunostaining of cardiac tissues for CD206.
[0027] FIG. 7D shows the effect of iPSC-EVs in modulating macrophage polarization in mice post myocardial infarction on CD206+ cell counts quantitatively.
[0028] FIG. 8 shows the distribution of small ncRNAs in iPSC-EVs and normal human dermal fibroblast extracellular vesicles (NHDF-EVs).
[0029] FIG. 9 shows the comparison of small non-coding RNAs (ncRNAs) and PlWI-interacting RNAs (piRNAs) in iPSC-EVs and NHDF-EVs.
[0030] FIG. 10 shows the list of the top 5 piRNAs by fold change.
[0031] FIG. 11A shows some non-limiting embodiments of sequences of RNA fragments for in vivo testing.
[0032] FIG. 11B is a schematic of the timeline and RNA dose of a mouse ER model.
[0033] FIG. 11C is a collection of representative images from TTC staining showing the infarct area in mouse heart after treatment with each of the different RNA fragments.
[0034] FIG. HD shows the quantitative analysis of the infarct size in mouse heart after treatment with each of the different RNA fragments.
[0035] FIG. HE shows the quantitative analysis of cTNI level in mouse heart after treatment with each of the different RNA fragments.
[0036] FIG. 11F shows the top 10 raw sequences in iPSC-EVs ranked by number of counts, with sequence alignments of piR-31068 to other top- 10 raw sequences; the sequence between nucleotides 6 and 28 is fully conserved.
[0037] FIG. HG shows a sequence comparison of piR-31068 and 4 truncated RNA candidates generated for functional screening.
[0038] FIG. 11 H shows representative images of infarct size as measured by TTC staining 48 hours post-MI from mice that had received each indicated RNA or Veh (vehicle).
[0039] FIG. Ill shows pooled data for infarct size measured 48 hours post-MI by TTC staining of hearts from mice that had received each indicated RNA or Veh. n = 4 animals per group.
[0040] FIG. 11 J shows quantification of plasma cTNI level in each indicated group 48 hours post-MI. n = 4 animals per group. Pooled data are expressed as mean ± SD. Statistical analysis was performed by one-way ANOVA, followed by Tukey’s test.
[0041] FIG. 12A shows a sequence comparison of mREXl and Scramble (Scr). The scrambled sequence was matched to mREXl in length (25 nt) and nucleotide composition, but in a randomized order.
[0042] FIG. 12B shows predicted secondary structures of mREXl and Scramble (left panels) by RNAfold Webserver. Predicted 3D structure of mREXl (right panel) by AlphaFold.
[0043] FIG. 12C shows a schematic of mREXl in vitro study design with BMDM.
[0044] FIG. 12D shows pooled data for IL-6 in BMDM as measured by qPCR in mREXl or control groups, n = 3 biological replicates per group. Statistical analysis by oneway ANOVA, followed by Tukey’s test.
[0045] FIG. 12E shows pooled data for TNF-alpha in BMDM as measured by qPCR in mREXl or control groups, n = 3 biological replicates per group. Statistical analysis by one-way ANOVA, followed by Tukey’s test.
[0046] FIG. 12F shows a schematic of mREXl in vivo study design.
[0047] FIG. 12G shows representative TTC-stained heart slices 48 hours post-MI from mice given mREXl or controls.
[0048] FIG. 12H shows pooled data for infarct size from mice in each of the indicated experimental groups; n = 4 animals per group. Statistical analysis was performed by one-way ANOVA, followed by Tukey’s test.
[0049] FIG. 121 shows pooled data for plasma cTNI levels in each of the indicated experimental groups 48 hours post-MI. n = 4 animals per group. Statistical analysis by oneway ANOVA, followed by Tukey’s test.
[0050] FIG. 12J shows representative immunofluorescent images of iNOS and a-SA showing Ml -like macrophages in the myocardium and pooled data in each of the indicated experimental groups. Scale bar, 100 pm. Statistical analysis by two tailed unpaired t test.
[0051] FIG. 12K shows representative immunofluorescent images of CD206 and a-SA showing M2-like macrophages in the myocardium and pooled data in each of the indicated experimental groups. Scale bar, 100 pm. Statistical analysis by two tailed unpaired t test.
[0052] FIG. 12L shows representative immunofluorescent images of CD68 and a-SA of macrophages in the myocardium and pooled data in each of the indicated experimental groups. Scale bar, 100 pm. Statistical analysis by two tailed unpaired t test.
[0053] FIG. 12M shows pooled data for fold changes of TNF-alpha as measured by qPCR in experimental group mREXl versus vehicle 48 hours post-MI. n = 4 animals per group. Statistical analysis by two tailed unpaired t test.
[0054] FIG. 12N shows pooled data for TGF-beta as measured by qPCR in the experimental group mREXl versus vehicle 48 hours post-MI. n = 4 animals per group. Statistical analysis was performed by two tailed unpaired t test. When error bars are shown, pooled data are expressed as mean ± SD.
[0055] FIG. 13A shows a schematic of the clodronate study design.
[0056] FIG. 13B shows representative images of TTC-stained heart sections 48 hours post-MI from mice given mREXl or vehicle (Veh), with or without prior clodronate injections.
[0057] FIGs. 13C-13D show pooled data for infarct size (FIG. 13C) or plasma TNI levels (FIG. 13D) 48 hours post-MI from mice that had received mREXl or vehicle, with or without prior clodronate injections, n = 4 animals per group. Statistical analysis was performed by one-way ANOVA, followed by Tukey’s test.
[0058] FIG. 13E shows a schematic showing the oral delivery study design.
[0059] FIG. 13F shows representative images of TTC-stained heart sections 48 hours post-MI from mice fed oral mREXl, vehicle, or Scr.
[0060] FIGs. 13G-13H show pooled data for infarct size (FIG. 13G) or plasma cTNI levels (FIG. 13H) in each of the indicated experimental groups; n = 4 animals per group. Statistical analysis was performed by one-way ANOVA, followed by Tukey’s test.
[0061] FIGs. 13I-13J show representative immunofluorescent images of iNOS (FIG. 131) or CD206 (FIG. 13J) colocalized with CD68 showing Ml-like macrophages after vehicle or mREXl, with corresponding pooled data. Scale bar, 100 pm. Statistical analysis was performed by two tailed unpaired t test. Pooled data are expressed as mean ± SD.
[0062] FIG. 14 shows representative histology images of the myocardium after treatments. Scale bar, 100 pm. Yellow arrows point to the myeloid cells.
[0063] FIG. 15A shows the distribution of top BLAST hits of mREXl.
[0064] FIG. 15B shows the overlap between mREXl and 3 different mRNA fragments (HES7, FCGR2A, LARP4B).
[0065] FIGs. 16A-16C show quantitative analysis of cytokine array results on BMDM, showing representative pro-inflammatory cytokines, including IL-6, IL- 12, and TNF-alpha. n = 3 biological replicates per group. Data are expressed as mean ± SD. Statistical analysis was performed by one-way ANOVA, followed by Tukey’s test.
[0066] FIG. 16D shows representative western blotting images of CD206 to show its expression level on BMDMs after mREXl and controlled treatments.
[0067] FIG. 16E shows quantitative analysis of western blotting results of CD206 to show its expression level on BMDMs after mREXl and controlled treatments. Data are expressed as mean ± SD. Statistical analysis was performed by one-way ANOVA, followed by Tukey’s test.
[0068] FIG. 17 shows the top 10 raw sequences counted in iPSC-EVs.
[0069] FIGs. 18A-18B depict the results of point mutation screening of mREXl derivatives. FIG. 18A depicts the design of mREXl derivative sequences by point mutation. FIG. 18B depicts the results of an immunomodulatory efficacy test in a macrophage model in vitro.
[0070] FIGs. 19A-19D depict the results of an assessment of cardioprotection of mREXl derivatives. FIG. 19A depicts a schematic showing the mouse I / R study design. FIG.19B depicts TTC staining showing the infarct area of mouse hearts after treatment and control. FIG. 19C depicts quantification of infarct size. FIG. 19D depicts cTNI level measured by ELISA, showing cardiac injury after treatment and control.
[0071] FIGs.20A-20B depict the results of a screening of mREXl derivatives with chemical modification. FIG. 20A depicts the design of mREXl derivative sequences by lockednucleic acid and phosphorothioate linkages. FIG. 20B depicts the results of qPCR in a macrophage model in vitro, showing decreased IL-6 level in the LNA group.
[0072] FIGs. 21A-21D depict the results of an assessment of cardioprotection of mREXl derivatives. FIG. 21A depicts the design of mREXl derivative sequences (named as “TM1”) by locked nucleic acid and phosphorothioate linkages. FIG. 2 IB depicts TTC staining showing the infarct area of mouse hearts after TM1 treatment and control. FIG. 21C depicts the results of quantification of infarct size. FIG. 2 ID depicts cTNI level measured by ELISA, showing cardiac injury after TM1 treatment and control.
[0073] FIGs. 22A-22C depict the results of an assessment of a stability assay of mREXl derivatives. FIG. 22A depicts a schematic showing the study design. Exonuclease RNase R is incubated with RNA derivatives and then tested by PCR. FIG. 22B depicts the results of an assessment where the change of Ct value in qPCR results in different groups. FIG.22C depicts the results of an assessment of stability of mREXl, TM1 exposed to increasing concentrations of RNase R.
[0074] FIG. 23 depicts the results of an assessment of RNA sequencing of macrophages after mREXl treatment. FIG. 23 depicts a volcano plot showing differentially expressed genes in mREXl treated group versus vehicle treated group (control).
[0075] FIGs. 24A-24C depict the results of an assessment of SLC7A11 as a potential target of mREXl in macrophages. FIG. 24A depicts the fold change of top genes in the treatment group vs. the vehicle control. FIG. 24B depicts quantification of CPM reads of SLC7A11 counts from RNA-seq results in the mREXl group and the vehicle group. FIG. 24C depicts qPCR results showing increased SLC7A11 transcriptional level in mREXl vs vehicle group.DETAILED DESCRIPTION
[0076] Myocardial infarction (MI), also known as “heart attack”, affects >800,000 individuals annually in the United States. Due to the heart's limited regenerative capacity, many MI survivors develop heart failure (HF), a progressive and life-threatening condition. Stem cell therapy, particularly using induced pluripotent stem cells (iPSCs) can be effective for post-MI cardiac repair. The discovery of iPSCs demonstrated that adult differentiated cells can be reprogrammed into pluripotent cells capable of differentiating into virtually any cell type, including cardiomyocytes (e.g., the beating cells of the human heart). Cardiomyocytes derivedfrom iPSCs are quite immature, such that they can induce potentially fatal arrhythmias when transplanted into primates post-MI. In some embodiments, the methods and compositions provided herein provide for the therapeutic potential of iPSCs without cell transplantation. Many of the benefits of iPSCs can be recapitulated by EVs, suggesting that EVs and their contents may be viable novel cell-free therapeutic candidates. In some embodiments, EVs secreted by iPSCs, and by iPSC-derived cardiomyocytes, act to speed the repair of injured tissue, with regenerative effects comparable to those of their parent cells but without risk of arrhythmias due to integration in tissue.
[0077] EVs can carry bioactive cargos — especially small noncoding RNAs — that modulate recipient cell behavior and tissue microenvironments. In some embodiments, iPSC-EVs exert therapeutic benefit in cardiac repair by delivering small noncoding RNAs that modulate inflammatory signaling in macrophages, key regulators of post-injury remodeling. In some embodiments, iPSC-EVs suppress inflammatory cytokines in macrophages and reduce myocardial injury in vivo, and their RNA cargo includes piRNAs and tRNA fragments. In some embodiments the regulatory RNAs (or noncoding RNAs) identified influence immune or reparative responses in other tissues, and can be relevant to a range of inflammatory and degenerative diseases.
[0078] Provided herein are methods of treating conditions associated with inflammation and / or fibrosis by administering a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of a PIWLinteracting RNA (piRNA) in EVs from induced pluripotent stem cells (iPSC-EVs) to a subject in need thereof. In some embodiments, administering a PlWI-interacting RNA (piRNA) in EVs from induced pluripotent stem cells (iPSC-EVs) to a subject suffering from a condition, e.g., condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle, ischemic cardiac muscle injury, a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition.Terms
[0079] As used herein, “nucleic acid” and “oligonucleotide” have their customary and ordinary meaning as understood by one of ordinary skill in the art in view of the present disclosure. “Nucleic acid” and “oligonucleotide” refer to multiple nucleotides (e.g., moleculescomprising a sugar (e.g. ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g. cytosine (C), thymidine (T) or uracil (U)) or a substituted purine (e.g. adenine (A) or guanine (G))), or analogues thereof. Deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) are nucleic acids in which the nucleotides are linked through a 3 ',5 '-phosphodiester bond to form a backbone of alternating phosphate groups and sugar moiety. RNA is composed of ribose sugar groups and DNA is composed of deoxyribose sugar groups. A nucleic acid includes polynucleosides (e.g., a polynucleotide minus the phosphate) and any other organic basecontaining polymer. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, thymidine, inosine, 5 -methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, 2,6-diaminopurine, hypoxanthine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties. Chemical modifications can be introduced at the site of the phosphodiester bond, sugar moiety, nucleobase, or combined sites thereof. Phosphorothioate (PS) oligonucleotides, are nucleic acids with a modified phosphate in which one of the non-bridging oxygens of the phosphate-ester group is changed to sulfur. This modification retains the negative charge of the backbone. They can have highly increased nuclease resistance relative to the natural nucleic acids. 2’-O-methylation is a modification on the ribose sugar of RNA in which a methyl group is added to the 2’ hydroxyl group of the native RNA. In “locked” nucleic acids (LNAs) the 2'-oxygen is attached to the 4'-carbon of the ribose sugar via a methylene bridge that locks in an RNA-like C3’-endo conformation. These derivatives are also known as 2',4'-bridged nucleic acids (BNA). The methylene bridge fixes the furanose ring in the 3'-endo conformation that is highly advantageous for base pairing. LNA can form very stable duplexes with RNA and DNA according to the Watson-Crick rule with excellent selectivity. The incorporation of LNA monomers into DNA oligomer can increase the strength of hybridization. A nucleic acid can include any other suitable modifications. Thus, the term nucleic acid also encompasses nucleic acids with substitutions or modifications, such as in the bases and / or sugars. Nucleic acid includes nucleotide analogues and polymers thereof, including, but not limited to, a polynucleoside in which two nucleosides are linked by a non-phosphodiester bond, e.g., linked by a phosphorothioate bond. “RNA molecule” as used herein denotes a nucleic acid that includes ribose as the sugar component, and derivatives thereof, including a nucleic acid that has been modified at the siteof the phosphodiester bond, sugar moiety, nucleobase, or combined sites thereof. As used herein, a “nucleobase sequence” denotes a sequence of nucleobases (e.g., cytosine (C), thymidine (T) / uracil (U), adenine (A) or guanine (G)) consecutively ordered along a backbone structure in a nucleic acid, e.g., along a sugar-phosphate backbone structure. As used herein, nucleotide sequence” and “nucleobase sequence” can be used interchangeably, unless indicated otherwise.
[0080] Nucleic acid molecules of the present disclosure may share a certain degree of sequence similarity or identity with the reference molecules (e.g., reference polypeptides or reference nucleic acid), for example, with art-described molecules (e.g., engineered or designed molecules or wild-type molecules). The term “identity” as known in the art, refers to a relationship between the sequences of two or more polypeptides or nucleic acids, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between them as determined by the number of matches between strings of two or more amino acid residues or nucleic acid residues. Identity measures the percent of identical matches between the smaller of two or more sequences with gap alignments (if any) addressed by a particular mathematical model or computer program (e.g., “algorithms”). Identity of related peptides can be readily calculated by known methods. “% identity” as it applies to polypeptide or nucleic acid sequences is defined as the percentage of residues (amino acid residues or nucleic acid residues) in the candidate amino acid or nucleic acid sequence that are identical with the residues in the amino acid sequence or nucleic acid sequence of a second sequence after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity. Any suitable methods and computer programs for the alignment can be used. It is understood that identity depends on a calculation of percent identity but may differ in value due to gaps and penalties introduced in the calculation. Generally, sequence variants of a particular nucleic acid or polypeptide have at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% but less than 100% sequence identity to that particular reference nucleic acid or polypeptide as determined by sequence alignment programs and parameters described herein and known to those skilled in the art. Such tools for alignment include those of the BLAST suite (Stephen F. Altschul, et al (1997), “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs”. Nucleic Acids Res. 25:3389-3402). Another popular localalignment technique is based on the Smith-Waterman algorithm (Smith, T. F. & Waterman, M. S. (1981) “Identification of common molecular subsequences.” J. Mol. Biol. 147:195-197.) A general global alignment technique based on dynamic programming is the Needleman -Wunsch algorithm (Needleman, S. B. & Wunsch. C. D. (1970) “A general method applicable to the search for similarities in the amino acid sequences of two proteins.” J. Mol. Biol. 48:443-453.). More recently a Fast Optimal Global Sequence Alignment Algorithm (FOGSAA) has been developed that purportedly produces global alignment of nucleobase and protein sequences faster than other optimal global alignment methods, including the Needleman-Wunsch algorithm. Other tools are described herein, specifically in the definition of “identity” below.
[0081] The term “identity” refers to the overall relatedness between polymeric molecules, for example, between nucleic acid molecules (e.g. DNA molecules and / or RNA molecules) and / or between polypeptide molecules. Calculation of the percent identity of two polynucleic acid sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second nucleic acid sequences for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or 100% of the length of the reference sequence. The nucleobase at corresponding positions are then compared. When a position in the first sequence is occupied by the same nucleobase as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a suitable mathematical algorithm. For example, the percent identity between two nucleic acid sequences can be determined using methods such as those described in Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects. Smith. D. W., ed., Academic Press. New York, 1993; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Computer Analysis of SequenceData, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey, 1994; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; each of which is incorporated herein by reference. For example, the percent identity between two nucleic acid sequences can be determined using the algorithm of Meyers and Miller (CABIOS, 1989, 4:11-17), which has been incorporated into the ALIGN program (version 2.0) using a PAM 120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleic acid sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix. Methods commonly employed to determine percent identity between sequences include, but are not limited to those disclosed in Carillo, H., and Lipman, D., SIAM J Applied Math., 48: 1073 (1988); incorporated herein by reference. Techniques for determining identity are codified in publicly available computer programs. Exemplary computer software to determine homology between two sequences include, but are not limited to, GCG program package, Devereux, J., et al., Nucleic Acids Research, 12(1), 387 (1984)), BLASTP, BLASTN, and FASTA Altschul, S. F. et al., J. Molec. Biol., 215, 403 (1990)).
[0082] The term “Watson-Crick base-pairing”, or “base-pairing” refers to the formation of hydrogen bonds between specific pairs of bases (“complementary base pairs”). For example, two hydrogen bonds form between adenine (A) and uracil (U), and three hydrogen bonds form between guanine (G) and cytosine (C). One method of assessing the strength of bonding between two nucleic acids is by quantifying the percentage of bonds formed between the guanine and cytosine bases of the two nucleic acids (“GC content”). The formation of a nucleic acid duplex via bonding of complementary base pairs can also be referred to as “hybridization”. Generally, two nucleic acids sharing a region of complementarity are capable, under suitable conditions, of hybridizing (e.g., via nucleic acid base pairing) to form a duplex structure. A region of complementarity can vary in size. In some embodiments, a region of complementarity ranges in length from about 2 base pairs to about 100 base pairs. In some embodiments, a region of complementarity ranges in length from about 5 base pairs to about 75 base pairs. In some embodiments, a region of complementarity ranges in length from about 10 base pairs to about 50 base pairs. In some embodiments, a region of complementarity ranges in length from about 20 base pairs to about 30 base pairs.
[0083] Isolated” as used herein with reference to an isolated biomolecule, e.g., a nucleic acid, has the ordinary and customary meaning to one of ordinary skill in the art in view of the present disclosure. An isolated biomolecule, e.g., an isolated nucleic acid, is generally in a non-natural environment, or in an environment that the biomolecule would otherwise not have been without human intervention of the biomolecule or its environment. In some embodiments, an isolated biomolecule is not inside a cell or an organism.
[0084] “Extracellular vesicle” or “EV” as used herein have their ordinary and customary meaning as understood by one of ordinary skill in the art, in view of the present disclosure. EVs include lipid bilayer structures generated by cells, and include exosomes, microvesicles, epididimosomes, argosomes, exosome-like vesicles, microparticles, promininosomes, prostasomes, dexosomes, texosomes, dex, tex, archeosomes and oncosomes.
[0085] As used herein, “extracellular vesicle-free” or “EV-free” denotes a composition or method that does not involve the use of EV, or a substantial amount of EV. In some embodiments, an EV-free composition is substantially free of EV.
[0086] “PIWLinteracting RNA” and “piRNA” are used interchangeably herein to refer to small, non-coding RNA of about 24 to about 32 nucleotides, e.g., about 26 to about 32 nucleotides long. Endogenous piRNA can associate with PIWI proteins (e.g., Piwi, Argonaute (such as Ago3), and Aubergine). Endogenous piRNA can be complementary to host transposable elements.
[0087] “Subject,” as used herein refers to any vertebrate animal, including mammals and non-mammals. A subject can include primates, including humans, and nonprimate mammals, such as rodents, domestic animals or game animals. Non-primate mammals can include mouse, rat, hamster, rabbit, dog, fox, wolf, cat, horse, cow, pig, sheep, goat, camel, deer, buffalo, bison, etc. Non-mammals can include bird (e.g., chicken, ostrich, emu, pigeon), reptile (e.g., snake, lizard, turtle), amphibian (e.g., frog, salamander), fish (e.g., salmon, cod, pufferfish, tuna), etc. The terms, “individual,” “patient,” and “subject” are used interchangeably herein.
[0088] “Administering” as used herein can include any suitable routes of administering a therapeutic agent or composition as disclosed herein. Suitable routes of administration include, without limitation, oral, parenteral, intravenous, intramuscular,subcutaneous, transdermal, airway (aerosol), pulmonary, cutaneous, injection or topical administration. Administration can be local or systemic.
[0089] As used herein, “treat” and “treatment” include curing, improving, ameliorating, reducing the severity of, preventing, slowing the progression of, and / or delaying the appearance of a disease, condition and / or symptoms thereof.
[0090] A treatment can be considered “effective,” or “therapeutically effective” as used herein, if one or more of the signs or symptoms of a condition described herein are altered in a beneficial manner, other clinically accepted symptoms are improved, or even ameliorated, or a desired response or outcome is induced e.g., by at least 2%, 3%, 4%, 5%, 10%, or more, following treatment according to the methods described herein. Efficacy can be assessed, for example, by measuring a marker, indicator, symptom, and / or the incidence of a condition treated according to the methods described herein or any other measurable parameter appropriate, e.g. exercise endurance. Efficacy can also be measured by a failure of an individual to worsen as assessed by hospitalization, or need for medical interventions (e.g., progression of the disease is halted). Treatment includes any treatment of a disease or condition in an individual or an animal (some non-limiting examples include a human or an animal) and includes: (1) inhibiting the disease or condition, e.g., preventing a worsening of symptoms (e.g. pain or inflammation); or (2) relieving the severity of the disease or condition, e.g., causing regression of symptoms. An effective amount for the treatment of a disease or condition means that amount which, when administered to a subject in need thereof, is sufficient to result in effective treatment as that term is defined herein, for that disease or condition. Efficacy of an agent can be determined by assessing physical indicators of a condition or desired response or outcome, (e.g., muscle function, mass, or volume, such as heart function, mass, or volume). One skilled in the art can monitor efficacy of administration and / or treatment by measuring any one of such parameters, or any combination of parameters.
[0091] The term “effective amount” or “therapeutically effective amount” as used herein refers to the amount of a composition or an agent needed to alleviate at least one or more symptom of the disease or condition, and relates to a sufficient amount of therapeutic composition to provide the desired effect. The term “effective amount” or “therapeutically effective amount” can refer to an amount of a composition or therapeutic agent that is sufficient to provide a particular anti-inflammatory, anti-fibrotic, immunomodulatory, myoprotectiveand / or cardioprotective effect when administered to a typical subject. An effective amount as used herein, in various contexts, can include an amount sufficient to delay the development of a symptom of the disease or condition, alter the course of a symptom disease or condition (for example but not limited to, slowing the progression of a symptom of the disease or condition), or reverse a symptom of the disease or condition. In some embodiments, the therapeutically effective amount is administered in one or more doses of the therapeutic agent. In some embodiments, the therapeutically effective amount is administered in a single administration, or over a period of time in a plurality of doses.
[0092] As used herein, the phrase “physiologically compatible” and “pharmaceutically acceptable” are employed interchangeably herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0093] Definitions of common terms in cell biology and molecular biology can be found in “The Merck Manual of Diagnosis and Therapy”, 19th Edition, published by Merck Research Laboratories, 2006 (ISBN 0-91 1910-19-0); Robert S. Porter et al. (eds.), The Encyclopedia of Molecular Biology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); Benjamin Lewin, Genes X, published by Jones & Bartlett Publishing, 2009 (ISBN-10: 0763766321); Kendrew et al. (eds.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8) and Current Protocols in Protein Sciences 2009, Wiley Intersciences, Coligan et al., eds.
[0094] The singular terms “a,” “an,” and “the” include plural referents unless context clearly indicates otherwise. Similarly, the word “or” is intended to include “and” unless the context clearly indicates otherwise. The abbreviation, “e.g.” is used herein to indicate a non-limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.” The term “about” as used herein to, for example, define the values and ranges of molecular weights means that the indicated values and / or range limits can vary within ±20%, e.g., within ±10%, including within ±5%. The use of “about” before a number includes the number itself. For example, “about 5” provides express support for “5.” Numbers providedin ranges include overlapping ranges and integers in between; for example a range of 1 -4 and 5-7 includes for example, 1-7, 1-6, 1-5, 2-5, 2-7, 4-7, 1, 2, 3, 4, 5, 6 and 7.NUCLEIC ACIDS
[0095] Provided herein is an isolated nucleic acid that includes: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), or a sequence having no more than 3 (e.g., no more than 2, no more than 1) substitutions thereto, where the nucleic acid is RNA. Also provided is an isolated nucleic acid that includes a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% identical to 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), e g., where the nucleic acid is RNA. In some embodiments, the isolated nucleic acid consisting of or consisting essentially of the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), e.g., where the nucleic acid is RNA. In some embodiments, the isolated nucleic acid is at most 35 nucleotides long. In some embodiments, the isolated nucleic acid is at most 27 nucleotides long.
[0096] Also provided herein is an isolated nucleic acid that includes: 5’-SGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 32), or a sequence having no more than 3 (e.g., no more than 2, no more than 1) substitutions thereto, where S is G or C, where the nucleic acid is RNA. In some embodiments, the isolated nucleic acid includes 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10). Also provided is an isolated nucleic acid that includes a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% identical to 5’- SGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 32), where S is G or C, or to 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10), where the nucleic acid is RNA. In some embodiments, the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11), or 5’-CGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 12). In some embodiments, the isolated nucleic acid is at most 27 nucleotides long. In some embodiments, the isolated nucleic acid includes a cytosine at position 1 of SEQ ID NO: 10. In some embodiments, the nucleotide sequence is at least 95% identical to 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, where S is G or C (SEQ ID NO:33).
[0097] Also provided is an isolated nucleic acid comprising one of the following nucleotide sequences, or a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or about 100% identical to: (a) 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:1), wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long; (b) 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10), wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 22 nucleotides long; (c) 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11), wherein the isolated nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long; or (d) 5’-CGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 12), wherein the isolated nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long.
[0098] In some embodiments, the isolated nucleic acid includes a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2), wherein K is G or U, or a sequence having no more than 3 (e.g., no more than 2, no more than 1) substitutions thereto. In some embodiments, K is G. In some embodiments, the isolated nucleic acid includes a nucleotide sequence of: 5’- GCAUGGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 8), or a sequence having no more than 3 (e.g., no more than 2, no more than 1) substitutions thereto. In some embodiments, K is U. In some embodiments, the isolated nucleic acid includes a nucleotide sequence of: 5’-GCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:9), or a sequence having no more than 3 (e.g., no more than 2, no more than 1) substitutions thereto.
[0099] In some embodiments, the isolated nucleic acid does not comprise: 5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:3). In some embodiments, the isolated nucleic acid is not 5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ IDN0:3).
[0100] The isolated nucleic acid can be any suitable length. In some embodiments, the nucleic acid is, is at most, or is about 35 nucleotides long. In some embodiments, the isolated nucleic acid is 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nucleotides long, or longer. In some embodiments, the isolated nucleic acid is, is about, or is at most 27bases (or nucleotides) long. In some embodiments, the isolated nucleic acid is, is about, or is at most 25 bases (or nucleotides) long.
[0101] A nucleic acid of the present disclosure can be single stranded or double stranded (e.g., RNA / DNA hybrid). In some embodiments, the nucleic acid is single stranded. As used herein, “single stranded” denotes that the nucleic acid, e.g., RNA, is not hybridized to or annealed to another nucleic acid molecule. In some embodiments, the single stranded RNA includes one or more portions that can hybridize or anneal to itself. In some embodiments, the single stranded RNA includes one or more portions that can form a stem-loop structure by hybridizing or annealing to itself.
[0102] An isolated nucleic acid of the present disclosure in some embodiments includes one or more chemically modified nucleotides, e.g., nucleotides with a modified backbone. In general, the chemical modification(s) is one that substantially preserves or enhances the therapeutic potency of the nucleic acid. Any suitable number of nucleotides of the nucleic acid can be chemically modified. In some embodiments, the nucleic acid includes 1 or more, 2 or more, 3 or more, 4 or more, 5 or more, 6 or more, 7 or more, 8 or more, 9 or more, 10 or more, 11 or more, 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 21 or more, 22 or more, 23 or more, 24 or more, 25 or more, 26 or more, 27 or more, 28 or more, 29 or more, 30 or more chemically modified nucleotides. In some embodiments, the nucleic acid includes 1-5, 1-6, 1-7, 1-8, 1-9, 1-10, 1-15, 1-20, 1-25, or 1-35 chemically modified nucleotides. In some embodiments, the nucleic acid includes 1-10 chemically modified nucleotides. In some embodiments, the nucleic acid includes 8 chemically modified nucleotides. In some embodiments, the nucleic acid includes 6 chemically modified nucleotides.
[0103] The chemically modified nucleotides can be distributed along the isolated nucleic acid in any suitable manner. In some embodiments, a residue or nucleotide of the isolated nucleic acid in the nucleotide sequence comprises the at least one chemically modified residue. In some embodiments, the nucleic acid includes at least one chemically modified residue within the first half of the nucleic acid, e.g., the 5’ half of the nucleic acid. In some embodiments, the nucleic acid includes at least one chemically modified residue within the second half of the nucleic acid, e.g., the 3’ half of the nucleic acid. In some embodiments, the nucleic acid includes at least one chemically modified residue within the first half of the nucleicacid, e.g., the 5’ half of the nucleic acid, and at least one chemically modified residue within the second half of the nucleic acid, e.g., the 3’ half of the nucleic acid. In some embodiments, the nucleic acid includes one or more chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more residues from the 5’ end of the nucleic acid. In some embodiments, the nucleic acid includes one or more chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more residues from the 3 ’ end of the nucleic acid. In some embodiments, no two chemically modified residues are adjacent each other in the nucleic acid. In some embodiments, the nucleic acid includes 1, 1, 2, 2, 3, 3, 4, 4, 5, 5 chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 residues, respectively, from the 5’ end of the nucleic acid. In some embodiments, the nucleic acid includes 1, 1, 2, 2, 3, 3, 4, 4, 5, 5 chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 residues, respectively, from the 3’ end of the nucleic acid. In some embodiments, the nucleic acid includes the same number of chemically modified residues in the 5’ half and 3’ half of the nucleic acid. In some embodiments, the nucleic acid includes 3 chemically modified residues within 5 nucleotides from the 5’ end of the nucleic acid and / or 3 chemically modified residues within 5 residues from the 3’ end of the nucleic acid.
[0104] In some embodiments, the chemically modified residue(s) is / are within the nucleotide sequence of 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), or sequence variant thereof (e.g., as provided herein, for example, within the nucleotide sequence of 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11)). In some embodiments, the nucleic acid includes at least one chemically modified residue within the first half of the nucleotide sequence, e.g., the 5’ half of the nucleotide sequence. In some embodiments, the nucleic acid includes at least one chemically modified residue within positions 1-13 of the nucleotide sequence. In some embodiments, the nucleic acid includes at least one chemically modified residue within the second half of the nucleotide sequence, e.g., the 3’ half of the nucleotide sequence. In some embodiments, the nucleic acid includes at least one chemically modified residue within positions 14-26 of the nucleotide sequence. In some embodiments, the nucleic acid includes at least one chemically modified residue within positions 1-13 of the nucleotide sequence, and at least one chemically modified residue within positions 14-26 of the nucleotide sequence. In some embodiments, the nucleic acid includes one or more chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more residuesfrom the 5’ end of the nucleotide sequence. In some embodiments, the nucleic acid includes one or more chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more residues from the 3 ’ end of the nucleotide sequence. In some embodiments, no two chemically modified residues are adjacent to each other in the nucleotide sequence. In some embodiments, the nucleic acid includes 1, 1, 2, 2, 3, 3, 4, 4, 5, 5 chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 residues, respectively, from the 5’ end of the nucleotide sequence. In some embodiments, the nucleic acid includes 1, 1, 2, 2, 3, 3, 4, 4, 5, 5 chemically modified residues within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 residues, respectively, from the 3’ end of the nucleotide sequence. In some embodiments, the nucleic acid includes the same number of chemically modified residues in the 5’ half and 3’ half of the nucleotide sequence. In some embodiments, the nucleic acid includes 3 chemically modified residues within 5 residues from the 5’ end of the nucleotide sequence and / or 3 chemically modified residues within 5 residues from the 3’ end of the nucleotide sequence. In some embodiments, the nucleic acid includes a different number of chemically modified residues in the 5’ half and 3’ half of the nucleotide sequence. In some embodiments, the nucleic acid includes a greater number of chemically modified residues in the 3’ half than in the 5’ half of the nucleotide sequence. In some embodiments, the nucleic acid includes 3 chemically modified residues within 5 residues from the 5’ end of the nucleotide sequence and / or 3, 4, or 5 chemically modified residues within 5 residues from the 3’ end of the nucleotide sequence.
[0105] In some embodiments, the isolated nucleic acid includes a chemically modified residue at one or more of positions 1, 3, 5, 21, 23, and 25 of the nucleotide sequence (e.g., as numbered according to SEQ ID NO:1, 15, or 33). In some embodiments, the isolated nucleic acid includes a chemically modified residue at one or more of positions 1, 3, 5, 18, 20, and 22 of the nucleotide sequence (e.g., as numbered according to SEQ ID NO: 10 or 33). In some embodiments, the isolated nucleic acid includes a chemically modified residue at positions 1, 3, 5, 21, 23, and 25 of the nucleotide sequence (e.g., as numbered according to SEQ ID NO: 1, 15, or 33). In some embodiments, the isolated nucleic acid includes a chemically modified residue at positions 1, 3, 5, 18, 20, and 22 of the nucleotide sequence (e.g., as numbered according to SEQ ID NO: 10 or 33). In some embodiments, the isolated nucleic acid has the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), or sequence variant thereof (e.g., as provided herein, for example, thenucleotide sequence of 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11)), where one or more (e.g., any 1, 2, 3, 4, 5, or all 6) of positions 1, 3, 5, 21, 23, and 25 of the nucleotide sequence are chemically modified residues. In some embodiments, the isolated nucleic acid has the nucleotide sequence 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10), where one or more (e.g., any 1, 2, 3, 4, 5, or all 6) of positions 1, 3, 5, 18, 20, and 22 of the nucleotide sequence are chemically modified residues. In some embodiments, the isolated nucleic acid comprises the chemically modified residue at one or more of the first, third and fifth residues from the 5’ end and the 3’ end of the nucleotide sequence (e.g., one or more of the first, third and fifth residues from the 5’ end, and one or more of the first, third and fifth residues from the 3’ end). In some embodiments, the isolated nucleic acid comprises the chemically modified residue at the first, third and fifth residues from the 5’ end and the 3’ end of the nucleotide sequence (e.g., at the first, third and fifth residues from the 5’ end, and at the first, third and fifth residues from the 3’ end). In some embodiments, the chemically modified residue(s) increases in vitro and / or in vivo stability of the nucleic acid, relative to a nucleic acid having the same nucleotide sequence where the residues are not chemically modified. In some embodiments, the chemically modified residue(s) increases therapeutic potency of the nucleic acid, e.g., for treating an inflammatory condition, cardiac injury, or sepsis, relative to a nucleic acid having the same nucleotide sequence where the residues are not chemically modified.
[0106] The isolated nucleic acid in some embodiments includes one type, or two or more different types of chemically modified nucleotides. In some embodiments, the chemically modified nucleotide has a methylene bridge connecting the 2’-0 atom and the 4’-C atom of the nucleotide sugar ring to lock the conformation (Locked Nucleic Acid (LNA)). In some embodiments, the isolated nucleic acid includes the nucleotide sequence 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), or sequence variant thereof (e.g., as provided herein, for example, the nucleotide sequence of 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11)), where the nucleic acid is RNA and one or more (e.g., any 1, 2, 3, 4, 5, or all 6) of positions 1, 3, 5, 21, 23, and 25 of the nucleotide sequence are LNA. In some embodiments, all six of positions 1, 3, 5, 21, 23, and 25 of the nucleotide sequence are LNA. In some embodiments, the isolated nucleic acid includes the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO:15), wherein the nucleic acid is RNA, and where positions 1, 3, 5, 21, 23, and 25 of thenucleotide sequence are LNA. Tn some embodiments, the isolated nucleic acid has the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO:15), wherein the nucleic acid is RNA, and where positions 1, 3, 5, 21, 23, and 25 of the nucleotide sequence are LNA. In some embodiments, the isolated nucleic acid includes the nucleotide sequence 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), or sequence variant thereof (e.g., as provided herein, for example, the nucleotide sequence of 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11)), where the nucleic acid is RNA and one or more (e.g., any 1, 2, 3, 4, 5, or all 6) of the first, third and fifth residues from the 5’ end and from the 3’ end of the nucleotide sequence are LNA. In some embodiments, the isolated nucleic acid includes the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 15), wherein the nucleic acid is RNA, and where the first, third and fifth residues from the 5’ end and from the 3’ end of the nucleotide sequence are LNA.
[0107] The isolated nucleic acid, in some embodiments, can include any suitable chemical modification. In some embodiments, the chemical modification is a backbone modification, e.g., modification of the sugar / phosphate backbone. In some embodiments, the chemical modification is a backbone sugar modification. In some embodiments, the chemically modified nucleotide includes a LNA. In some embodiments, the chemical modification includes the introduction of a phosphorothioate group as linker between nucleotides. Suitable backbone modifications of the chemically modified nucleotides include, without limitation, phosphorothioates, phosphotriesters, methyl phosphonates, short chain alkyl or cycloalkyl intersugar linkages or short chain heteroatomic or heterocyclic intersugar linkages. In some embodiments, the chemical modification is a base modification.
[0108] In some embodiments, the isolated nucleic acid comprises a phosphorothioate bond between at least one pair of nucleic acid residues that are adjacent each other in the nucleotide sequence. The isolated nucleic acid can include any suitable number of phosphorothioate bonds within the nucleotide sequence of 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), or sequence variant thereof (e.g., as provided herein, for example, within the nucleotide sequence of 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11)). In some embodiments, the isolated nucleic acid includes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,22, 23, or 24 phosphorothioate bonds within the nucleotide sequence of 5’- GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), or sequence variant thereof (e.g., as provided herein, for example, within the nucleotide sequence of 5’- GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11)). In some embodiments, the isolated nucleic acid includes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, or 24 phosphorothioate bonds within the nucleotide sequence of SEQ ID NO: 1, 15, or 33. In some embodiments, the isolated nucleic acid includes a phosphorothioate bond between each pair of nucleic acid residues that are adjacent each other in the nucleotide sequence of SEQ ID NO: 1, 15, or 33. In some embodiments, the isolated nucleic acid does not include any phosphodiester bond, e.g., within SEQ ID NO: 1, 15, or 33.
[0109] The nucleic acids of the present disclosure can be prepared using any suitable option. Suitable options include, without limitation, chemical synthesis, enzymatic production and / or biological production. In some embodiments, the nucleic acids are prepared using chemical synthesis. Any suitable option for chemical synthesis of nucleic acids can be used. Suitable options include, without limitation, phosphodiester, phosphotriester, phosphoramidite, phosphite-triester, and solid phase synthesis approaches. In some embodiments, preparing the nucleic acids includes in vitro transcription. In some embodiments, the nucleic acids are prepared using recombinant DNA technology. In some embodiments, the nucleic acids are prepared by chemically modifying an unmodified nucleic acid having a nucleotide sequence of interest.Modifications to mREXl (SEQ ID NO: 11
[0110] In some embodiments, the isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1) or a sequence having no more than 3 substitutions thereto comprises one or more point mutations and / or one or more chemical modifications. In some embodiments, the isolated nucleic acid comprises a nucleotide sequence of any one of SEQ ID NOs: 10-16, or a sequence having no more than 3 substitutions thereto. In some embodiments, the nucleotide sequence comprises or consists of any one of SEQ ID NOs: 10-16. In some embodiments, the isolated nucleic acid is used in the treatment of a condition associated with inflammation and / or fibrosis, which comprises inflammation and / or fibrosis of the heart or skeletal muscle. In some embodiments, the condition associated with inflammation and / or fibrosis comprises a symptom and / or sequelaeof heart failure or myocardial infarction. In some embodiments, the condition associated with inflammation and / or fibrosis comprises ischemic cardiac muscle injury. In some embodiments, the therapeutically effective amount of the nucleic acid is administered to the subject intravenously, intramuscularly, or intracardially.[OlH] In some embodiments, a method of immunomodulation is provided, comprising contacting an effective amount of an isolated nucleic acid comprising a nucleotide sequence of any one of SEQ ID NOs: 10-16 with a population of macrophages, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is, or is about 25 nucleotides long. In some embodiments, the contacting comprises administering to a subject in need of treating a condition associated with inflammation and / or fibrosis the effective amount of the isolated nucleic acid. In some embodiments, the macrophage is a human macrophage. In some embodiments, the contacting is done in vitro. In some embodiments, contacting the effective amount of the isolated nucleic acid reduces expression of one or more pro-inflammatory cytokines in the population of macrophages, optionally wherein the one or more pro-inflammatory cytokines comprises one or more of: CD40, IL-6, or IL-12. In some embodiments, the nucleic acid comprises at least one chemically modified nucleotide. In some embodiments, the at least one chemically modified nucleotide comprises a backbone modification. In some embodiments, the backbone modification comprises one or more phosphorothioate linkages. In some embodiments, the backbone modification comprises a backbone sugar modification. In some embodiments, the backbone sugar modification comprises one or more locked nucleic acids.
[0112] In some embodiments, an isolated nucleic acid is provided, comprising a nucleotide sequence of any one of SEQ ID NOs: 10-16, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long. In some embodiments, an isolated nucleic acid comprising a nucleotide sequence at least 95% identical to any one of SEQ ID NOs: 10-16, wherein the nucleic acid is RNA, wherein the isolated nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long. In some embodiments, the nucleic acid comprises at least one chemically modified nucleotide. In some embodiments, the at least one chemically modified nucleotide comprises a backbone modification. In some embodiments, the backbone modification comprises one or more phosphorothioate linkages. In some embodiments, thebackbone modification comprises a backbone sugar modification. In some embodiments, the backbone sugar modification comprises one or more locked nucleic acids.
[0113] In some embodiments, the isolated nucleic acid is provided for use in the treatment of (a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or (b) ischemic cardiac muscle injury; or (c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition. In some embodiments, the isolated nucleic acid is provided for use in the preparation of a medicament for the treatment of (a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or (b) ischemic cardiac muscle injury; or (c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition. In some embodiments, the heart condition comprises a symptom and / or sequelae of heart failure. In some embodiments, a kit is provided, comprising: the isolated nucleic acid; and a pharmaceutically acceptable excipient.COMPOSITIONS
[0114] Also provided herein are compositions that find use in treating a condition associated with inflammation and / or fibrosis. The composition can include a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of a ncRNA in EVs from induced pluripotent stem cells (iPSC-EVs), or a sequence at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more) identical thereto. In some embodiments, the ncRNA includes PlWI-interacting RNA (piRNA). In some embodiments, the composition includes a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of ncRNA (e.g., a PlWI-interacting RNA (piRNA)) in EVs from induced pluripotent stem cells (iPSC-EVs), or a sequence having (i) no more than 3 substitutions thereto, and / or (ii) a truncation of no more than 10 nucleotides thereof, wherein the nucleic acid is RNA, and wherein the nucleic acid is at most 35 nucleotides long. In some embodiments, the ncRNA is a piRNA. In some embodiments, the nucleotide sequence is complementary to a sequence within an mRNA of one or more genes in the transcriptome (e.g., human transcriptome where the iPSC is a human iPSC), or a sequence at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more) identical thereto. Insome embodiments, the nucleotide sequence is complementary to a sequence within an mRNA of at least two genes in the transcriptome (e.g., human transcriptome where the iPSC is a human iPSC), or a sequence at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more) identical thereto. In some embodiments, the nucleotide sequence is complementary to a sequence within an mRNA of at least three genes in the transcriptome (e.g., human transcriptome where the iPSC is a human iPSC), or a sequence at least 90% (e.g., at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more) identical thereto. In some embodiments, the at least three genes are or include HES7, FCGR2A, and LARP4B. In some embodiments, the composition includes a pharmaceutically acceptable excipient. In some embodiments, the iPSC is a human iPSC. In some embodiments, the iPSC is a peripheral blood mononuclear cell (PBMC)-derived iPSC. In some embodiments, the composition is an EV-free composition. In some embodiments, the therapeutically effective amount of the isolated nucleic acid is an amount that, when administered to a subject, can bring about a desired outcome in the subject in need of treatment of a condition or disease (e.g., a condition associated with inflammation and / or fibrosis, a muscle disorder or symptom thereof, etc.) as described herein. In some embodiments, the therapeutically effective amount of the nucleic acid is sufficient on its own to bring about the desired outcome (e.g., without administering another therapeutic agent for the same condition or disease).
[0115] In some embodiments, the iPSC are human iPSC. In some embodiments, the iPSC are peripheral blood mononuclear cell (PBMC)-derived iPSC. In some embodiments, the iPSC express one or more pluripotency markers, such as, without limitation, Oct4, Sox2, and / or Nanog. The iPSC can be generated using any suitable option. In some embodiments, the iPSC are generated by reprogramming somatic cells (such as PBMC) to express one or more reprogramming factors selected from: Oct3 / 4, Sox2, KLF4, L-Myc, shp53, and / or Lin28. Reprogramming the somatic cells can be done using any suitable option (e.g., using episomal vectors encoding one or more of the reprogramming factors).
[0116] The iPSC-EV can be obtained using any suitable option. EV, in several embodiments, are isolated from cellular preparations by methods comprising one or more of filtration, centrifugation, antigen-based capture and the like. For example, in several embodiments, a population of cells grown in culture are collected and pooled. In several embodiments, monolayers of cells are used, in which case the cells are optionally treated inadvance of pooling to improve cellular yield (e.g., dishes are scraped and / or enzymatically treated with an enzyme such as trypsin to liberate cells). In some embodiments, cells are grown / maintained in serum-free medium, and conditioned media containing EV are collected using any suitable option (e.g., aspiration). In some embodiments, conditioned media is collected about every 24, 36, 48, 60, 72 hours or more, or a time interval in a range defined by any two of the preceding values (e.g., 24-72 hours, 24-60 hours, 36-48 hours, etc.). In some embodiments, the conditioned medium is frozen (e.g., at -80°C) before further processing to isolate EV. In some embodiments, two or more batches of the conditioned media are pooled before further processing to isolate EV. In some embodiments, conditioned medium or the pooled conditioned media are subject to one or more rounds of centrifugation (in several embodiments ultracentrifugation and / or density centrifugation is employed) in order to separate the EV fraction from the remainder of the cellular contents and debris in the conditioned media. In some embodiments, size exclusion filtration is used in conjunction with, or in place of centrifugation, in order to collect a particular size (e.g., diameter) of EV. In several embodiments, filtration need not be used. In still additional embodiments, EV (or subpopulations of EV are captured by selective identification of unique markers on or in the EV (e.g., transmembrane proteins)). In such embodiments, the unique markers can be used to selectively enrich a particular EV population. In some embodiments, enrichment, selection, or filtration based on a particular marker or characteristic of EV is not performed.
[0117] EVs, e.g., exosomes, disclosed herein can vary in size, depending on the embodiment. Depending on the embodiment, the size of the EVs ranges in diameter from about 15 nm to about 95 nm in diameter, including about 15 nm to about 20 nm, about 20 nm to about 30 nm, about 30 nm to about 40 nm, about 40 nm to about 50 nm, about 50 nm to about 60 nm, about 60 nm to about 70 nm, about 70 nm to about 80 nm, about 80 nm to about 90 nm, about 90 nm to about 95 nm, and overlapping ranges thereof. In several embodiments, EVs are larger (e.g., those ranging from about 140 to about 210 nm, including about 140 nm to about 150 nm, about 150 nm to about 160 nm, about 160 nm to about 170 nm, about 170 nm to about 180 nm, about 180 nm to about 190 nm, 190 nm to about 200 nm, about 200 nm to about 210 nm, and overlapping ranges thereof). In some embodiments, the EV diameter is in a range of about 15 nm to about 200 nm in diameter, including about 15 nm to about 20 nm, about 20 nm to about 30 nm, about 30 nm to about 40 nm, about 40 nm to about 50 nm, about50 nm to about 60 nm, about 60 nm to about 70 nm, about 70 nm to about 80 nm, about 80 nm to about 90 nm, about 90 nm to about 100 nm, about 100 nm to about 110 nm, about 110 nm to about 120 nm, about 120 nm to about 130 nm, about 130 nm to about 140 nm, about 140 nm to about 150 nm, about 150 nm to about 160 nm, about 160 nm to about 170 nm, about 170 nm to about 180 nm, about 180 nm to about 190 nm, about 190 nm to about 200 nm, and overlapping ranges thereof. In some embodiments, the EVs that are generated from the original cellular body are 100, 200, 300, 400, 500, 600, 700, 800, 900, 1,000, 2,000, 5,000, or 10,000 times smaller in at least one dimension (e.g., diameter) than the original cellular body.
[0118] The RNA species in the iPSC-EV can be determined using any suitable option. In some embodiments, the RNA sequences in the iPSC-EV is determined by sequencing (e.g., high-throughput sequencing or next generation sequencing, Sanger sequencing, etc.). In some embodiments, candidate RNA species (e.g., non-coding RNA (ncRNA), including piRNA, miRNA, and / or tRNA) for therapeutic use as described herein are identified by comparing the abundance of the RNA species in the iPSC-EV relative to a suitable reference (e.g., EV isolated from a non-therapeutic cell type, such as but not limited to normal human dermal fibroblasts (NHDF), or non-therapeutic EV, such as EV from NHDF). In some embodiments, a candidate ncRNA species is enriched in iPSC-EV relative to EV from NHDF. In some embodiments, a candidate ncRNA species is enriched in iPSC-EV relative to EV from NHDF by, by about or by at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 4, 5, 10, 20, 30, 40, 50, 100, 200, 500, or 1000 fold, or optionally it is enriched by a fold amount in a range defined by any two or the preceding values (e.g., 1.1-1000 fold, 5-100 fold, 10-1000 fold, 2-200 fold, 1.1-5 fold, 1.2-4 fold, 1.5-3 fold, 1.8-2 fold, etc.). In some embodiments, a candidate piRNA species is enriched in iPSC-EV relative to EV from NHDF. In some embodiments, a candidate piRNA species is enriched in iPSC-EV relative to EV from NHDF by at least 2 fold. In some embodiments, a candidate piRNA species is enriched in iPSC-EV relative to EV from NHDF by at least 10 fold. In some embodiments, a candidate piRNA species is enriched in iPSC-EV relative to EV from NHDF by at least 100 fold. In some embodiments, a therapeutic ncRNA species is enriched in iPSC-EV relative to EV from NHDF by, by about or by at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 4, 5, 10, 20, 30, 40, 50, 100, 200, 500, or 1000 fold, or optionally it is enriched by a fold amount in a range defined by any two or the preceding values (e.g., 1.1-1000 fold, 5-100 fold, 10-1000 fold, 2-200 fold,1.1-5 fold, 1.2-4 fold, 1.5-3 fold, 1.8-2 fold, etc.) In some embodiments, a therapeutic ncRNA (e.g., piRNA) species is enriched in iPSC-EV relative to EV from NHDF. In some embodiments, a therapeutic ncRNA (e.g., piRNA) species is enriched in iPSC-EV relative to EV from NHDF by at least 2 fold. In some embodiments, a therapeutic ncRNA (e.g., piRNA) species is enriched in iPSC-EV relative to EV from NHDF by at least 10 fold. In some embodiments, a therapeutic ncRNA (e.g., piRNA) species is enriched in iPSC-EV relative to EV from NHDF by at least 100 fold.
[0119] In some embodiments, the isolated nucleic acid includes a nucleotide sequence of a ncRNA (e.g., piRNA) in iPSC-EVs. In some embodiments, the isolated nucleic acid includes a sequence having up to 3 (or up to 2, or up to 1) substitution(s) to the nucleotide sequence of the ncRNA (e.g., piRNA) in iPSC-EVs. In some embodiments, the isolated nucleic acid includes a sequence having a truncation of no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotide(s) of the nucleotide sequence of the ncRNA (e.g., piRNA) in iPSC-EVs. As used herein, “truncation” denotes that one or more consecutive nucleotide residues from the 5’ and / or 3’ end of the reference sequence (e.g., a nucleotide sequence of a ncRNA (e.g., piRNA) in iPSC-EVs) is deleted. In some embodiments, the isolated nucleic acid includes a sequence having up to 3 (or up to 2, or up to 1) substitution(s) to the nucleotide sequence of the piRNA) in iPSC-EVs; and includes a sequence having a truncation of no more than 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 nucleotide(s) of the nucleotide sequence of the ncRNA (e.g., piRNA) in iPSC-EVs. In some embodiments, the truncation is a truncation from the 5’ end of the nucleotide sequence of the ncRNA (e.g., piRNA) in iPSC-EVs. In some embodiments, the truncation is a truncation from the 3’ end of the nucleotide sequence of the ncRNA (e.g., piRNA) in iPSC-EVs.
[0120] In some embodiments, the nucleotide sequence is selected from: 5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:3); 5’-GCCCGGCUAGCUCAGUCGGUAGAGCAUGAGAC-3’ (SEQ ID NO: 4); 5’-GGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 5); 5’- AUUGGUGGUUCAGUGGUAGAAUUCUCGCCUG-3’ (SEQ ID NO: 6); or 5’-UUGGUGGUUCAGUGGUAGAAUUCUCGCCUGCC-3’ (SEQ ID NO: 7). In some embodiments, the composition includes any 1, 2, 3, 4, or all 5 of SEQ ID NOs: 3-7. In some embodiments, the isolated nucleic acid comprises a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3 ’ (SEQ ID NO: 1) or a sequence having no morethan 3 substitutions thereto. In some embodiments, the isolated nucleic acid comprises a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2), wherein K is G or U, or a sequence having no more than 3 substitutions thereto. In some embodiments, the nucleic acid consists of or consists essentially of the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).
[0121] The isolated nucleic acid of the composition can be any suitable length. In some embodiments, the nucleic acid is, is at most, or is about 35 nucleotides long. In some embodiments, the isolated nucleic acid is 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 nucleotides long, or longer. In some embodiments, the isolated nucleic acid is, is about, or is at most 25 bases long.
[0122] In some embodiments, the isolated nucleic acid of the composition includes at least one chemically modified nucleotide, as described herein.
[0123] Also provided herein are compositions that include one or more of the isolated nucleic acids of the present disclosure. In some embodiments, the composition includes a pharmaceutically acceptable excipient. Some non-limiting examples of materials which can serve as pharmaceutically acceptable excipients include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as com starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxymethyl cellulose, methylcellulose, ethyl cellulose, microcrystalline cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricating agents, such as magnesium stearate, sodium lauryl sulfate and talc; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffered solutions; (21) polyesters, polycarbonates and / or polyanhydrides; (22) bulking agents, such as polypeptides and amino acids (23) serum component, such as serum albumin, HDL and LDL; (24) C2-C12 alcohols, such as ethanol; and (25) other non-toxic compatible substances employed in pharmaceutical formulations. In some embodiments, the pharmaceutically acceptable excipient is or includes phosphate buffered saline (PBS).
[0124] In some embodiments, the composition includes a transfection reagent, e.g., to promote delivery of the nucleic acid to a target cellular target (in vitro or in vivo). Any suitable transfection reagent can be included in the composition. Suitable transfection reagents include, without limitation, a liposome, extracellular vesicle (EV), and a polyethylene glycol (PEG)-cationic lipid complex (PCLC). In some embodiments, the transfection reagent includes a lipid (e.g., a liposome-forming lipid), or a PEGylated lipid. In some embodiments, the lipid is a cationic lipid, as provided herein. In some embodiments, the transfection reagent includes DharmaFECT® or Lipofectamine®. In some embodiments, the nucleic acid of the present disclosure is formulated with the transfection reagent in the composition so as to promote cellular uptake and / or pharmacokinetics of the nucleic acid.
[0125] Liposomes are artificially-prepared vesicles which may primarily be composed of a lipid bilayer and may be used as a delivery vehicle for the administration of pharmaceutical formulations. Liposomes can be of different sizes such as, but not limited to, a multilamellar vesicle (MLV), which may be hundreds of nanometers in diameter and may contain a series of concentric bilayers separated by narrow aqueous compartments, a small unicellular vesicle (SUV), which may be smaller than 50 nm in diameter, and a large unilamellar vesicle (LUV), which may be between 50 and 500 nm in diameter. Liposome design may include, without limitation, opsonins or ligands in order to improve the attachment of liposomes to target tissue / cells, or to activate events such as, but not limited to, endocytosis. Liposomes may contain a low or a high pH in order to improve the delivery of the cargo, e.g., a nucleic acid of the present disclosure.
[0126] In some embodiments, the composition includes, without limitation, liposomes such as those formed from l,2-dioleyloxy-N,N-dimethylaminopropane (DODMA) liposomes, DiLa2 liposomes from Marina Biotech (Bothell, Wash.), l,2-dilinoleyloxy-3-dimethylaminopropane (DLin-DMA), 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[l,3]-dioxolane (DLin-KC2-DMA), and MC3 and liposomes such as, but not limited to, DOXIL® from Janssen Biotech, Inc. (Horsham, Pa.).
[0127] In some embodiments, the composition includes a cationic lipid. Any suitable cationic lipid may be used in the present compositions. Suitable cationic lipids include, without limitation, DLin-DMA, DLin-D-DMA, DLin-MC3-DMA, DLin-KC2-DMA, DODMA and amino alcohol lipids. In some embodiments, the composition includes a cationiclipid complex, e.g., a polyethylene glycol (PEG)-cationic lipid complex (PCLC). In some embodiments, the cationic lipid is PEGylated, e.g., 2 kDa PEG (“PEG2000”). Any suitable option can be used to PEGylate the cationic lipid. In some embodiments, PCLC is formed by exposing a mixture of PEG and the cationic lipid to one or more freeze / thaw cycles, e.g., 1, 2, 3, 4, 5 or more freeze / thaw cycles. In some embodiments, a freeze / thaw cycle includes freezing the mixture with liquid nitrogen (e.g., around -190 °C) for about 5 minutes, and thawing at about 60 °C for about 5 minutes. A nucleic acid of the present disclosure can be mixed with the PCLC to generate a complex of the nucleic acid and the PCLC.
[0128] In some embodiments, the composition includes casein, e.g., a casein micelle. In some embodiments, the composition includes chitosan. In some embodiments, the composition includes casein and chitosan, e.g., a casein-chitosan micelle. In some embodiments, the composition includes a casein-chitosan complex. In some embodiments, the isolated nucleic acid in the composition is encapsulated in a casein-chitosan complex. In some embodiments, the composition includes one or more of phosphoproteins: alpha si casein, alpha s2 casein, beta casein, and kappa casein. In some embodiments, the composition includes two or more, three or more, or all four phosphoproteins: alpha si casein, alpha s2 casein, beta casein, and kappa casein. The phosphoproteins may be present in the composition at any suitable concentration (relative to each other, and relative to the total volume of the composition), and in some embodiments, is present in an amount suitable for forming casein micelles. In some embodiments, the casein phosphoproteins are collectively present in the composition at about 5-10 % (weight by volume). In some embodiments, the casein phosphoproteins are collectively present in the composition at about 8 % (weight by volume). In some embodiments, the casein phosphoproteins are collectively present in the composition at about 5 % (weight by volume). The casein phosphoproteins can be those from any suitable animal, e.g., mammal such as, but not limited to, human, non-human primate, cow, pig, horse, camel, goat, and sheep. In some embodiments, the casein phosphoproteins are bovine alpha si casein, alpha s2 casein, beta casein, and kappa casein. Suitable casein formulations with EV are provided in, e.g., Aminzadeh et al., J Extracell Vesicles. 2021 Jan;10(3):el2045, the entirety of which is incorporated herein by reference. In some embodiments, a composition, e.g., pharmaceutical composition, of the present disclosure formulated with casein, as provided herein, is suitable for oral administration to the subject. Suitable oral formulations for thenucleic acids of the present disclosure are provided in, e.g., International Application Nos. PCT / US2022 / 035866 (fded June 30, 2022) and PCT / US2022 / 035870 (fded June 30, 2022), each of which is incorporated herein by reference in its entirety. In some embodiments, an oral formulation of the present disclosure includes any one or more nucleic acids described herein; a cationic lipid; at least one casein protein; and a chitosan. In some embodiments, the oral formulation includes an isolated nucleic acid that includes a nucleotide sequence of UCCCUGGUGGUCUAGUGGUUAGGAUUCGGCGC (SEQ ID NO: 1); a cationic lipid; at least one casein protein; and a chitosan. In some embodiments, an oral formulation includes an artificial lipid micelle or a liposome; any one or more nucleic acids described herein, wherein the one or more nucleic acids is encapsulated within the artificial lipid micelle or the liposome; and a coating on the artificial lipid micelle or the liposome, wherein the coating comprises a mixture of casein proteins and chitosan polymers. In some embodiments, an oral formulation includes an artificial lipid micelle or a liposome; an isolated nucleic acid that includes a nucleotide sequence of UCCCUGGUGGUCUAGUGGUUAGGAUUCGGCGC (SEQ ID NO: 1), wherein the nucleic acid is encapsulated within the artificial lipid micelle or the liposome; and a coating on the artificial lipid micelle or the liposome, wherein the coating comprises a mixture of casein proteins and chitosan polymers. In some embodiments, the artificial lipid micelle includes a cationic lipid micelle. In some embodiments, the liposome includes cationic lipids. In some embodiments, the liposome includes DharmaFECT® or Lipofectamine®.
[0129] In some embodiments, the composition is in a parenteral dosage form. In some embodiments, the parenteral dosage form is sterile or capable of being sterilized before administering to a patient. Examples of parenteral dosage forms include, but are not limited to, solutions ready for injection, dry products ready to be dissolved or suspended in a pharmaceutically acceptable vehicle for injection, suspensions ready for injection, and emulsions. In addition, controlled-release parenteral dosage forms can be prepared for administration to a subject. Suitable excipients that can be used to provide parenteral dosage forms of the nucleic acid include, without limitation: sterile water; water for injection USP; saline solution; glucose solution; aqueous vehicles such as but not limited to, sodium chloride injection, Ringer's injection, dextrose injection, dextrose and sodium chloride injection, and lactated Ringer's injection; water-miscible vehicles such as, but not limited to, ethyl alcohol,polyethylene glycol, and propylene glycol; and non-aqueous vehicles such as, but not limited to, com oil, cottonseed oil, peanut oil, sesame oil, ethyl oleate, isopropyl myristate, and benzyl benzoate.
[0130] In some embodiments, the isolated nucleic acid comprising a nucleotide sequence of GGUGGUUCAGUGGUAGAAUUCUCGC (SEQ ID NO: 1) is used for the treatment of (a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or (b) ischemic cardiac muscle injury; or (c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition. In some embodiments, the isolated nucleic acid comprising a nucleotide sequence at least 95% identical to GGUGGUUCAGUGGUAGAAUUCUCGC (SEQ ID NO: 1) is used for the treatment of (a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or (b) ischemic cardiac muscle injury; or (c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition. In some embodiments, the isolated nucleic acid comprising a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2) is used for the treatment of (a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or (b) ischemic cardiac muscle injury; or (c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition. In some embodiments, the isolated nucleic acid comprising a nucleotide sequence of: 5’- AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:3) is used for the treatment of (a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or (b) ischemic cardiac muscle injury; or (c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition.
[0131] In some embodiments, the isolated nucleic acid comprising a nucleotide sequence of GGUGGUUCAGUGGUAGAAUUCUCGC (SEQ ID NO: 1) is used in the preparation of a medicament for the treatment of: (a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or (b) ischemic cardiac muscle injury; or (c) a muscle disorder or a symptomthereof, optionally wherein the muscle disorder comprises a heart condition. In some embodiments, the isolated nucleic acid comprising a nucleotide sequence at least 95% identical to GGUGGUUCAGUGGUAGAAUUCUCGC (SEQ ID NO: 1) is used in the preparation of a medicament for the treatment of: (a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or (b) ischemic cardiac muscle injury; or (c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition. In some embodiments, the isolated nucleic acid comprising a nucleotide sequence of: 5’- GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2) is used in the preparation of a medicament for the treatment of: (a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or (b) ischemic cardiac muscle injury; or (c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition. In some embodiments, the isolated nucleic acid comprising a nucleotide sequence of: 5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:3) is used in the preparation of a medicament for the treatment of: (a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or (b) ischemic cardiac muscle injury; or (c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition.METHODS
[0132] Provided herein are methods of treating a subject in need thereof using the isolated nucleic acid of the present disclosure (also referred to herein as “treatment methods”). Conditions that may be treated by the treatment methods include, without limitation, inflammation and / or fibrosis of the heart or skeletal muscle, heart failure, myocardial infarction, and ischemic cardiac muscle injury. In some embodiments, the conditions include, without limitation, muscular disorders, myocardial infarction, cardiac disorders, myocardial alterations, muscular dystrophy, fibrotic disease, inflammatory disease, viral infection, sepsis or wound healing. In some embodiments, conditions treated by the treatment methods include, without limitation, conditions associated with inflammation and / or fibrosis. In some embodiments, a subject treated by administering the isolated nucleic acids of the present disclosure, according to the treatment methods herein, are in need of treatment for conditionsassociated with inflammation and / or fibrosis. The conditions associated with inflammation and / or fibrosis can include, without limitation, inflammation and / or fibrosis of the heart or skeletal muscle. In some embodiments, the conditions treated by the present treatment methods are a symptom and / or sequelae of heart failure. In some embodiments, the method includes administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a therapeutically effective amount of the isolated nucleic acids of the present disclosure. In some embodiments, administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a therapeutically effective amount of the isolated nucleic acids of the present disclosure treats the subject for the condition associated with inflammation and / or fibrosis.
[0133] In some embodiments, a treatment method of the present disclosure treats any one or more of a variety of inflammatory conditions. In some embodiments, the inflammatory condition is a chronic condition. In some embodiments, the inflammatory condition comprises immunosuppression subsequent to a hyperinflammatory response. In some embodiments, the inflammatory condition includes an autoimmune disease, graft-versus-host disease (GVHD) or an immune response to an organ transplant. In some embodiments, the inflammatory condition includes viral infection, sepsis, arthritis (rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis), multiple sclerosis, pemphigus, and type 1 diabetes (also referred to as insulin-dependent diabetes mellitus (IDDM)). In some embodiments, the inflammatory condition includes Behqet's disease, polymyositis / dermatomyositis, autoimmune cytopenias, autoimmune myocarditis, primary liver cirrhosis, Goodpasture's syndrome, autoimmune meningitis, Sjogren's syndrome, systemic lupus erythematosus, Addison's disease, alopecia greata, ankylosing spondylitis, autoimmune hepatitis, autoimmune mumps, Crohn's disease, insulin-dependent diabetes mellitus, dystrophic epidermolysis bullosa, epididymitis, glomerulonephritis, Graves' disease, Guillain-Barre syndrome, Hashimoto's disease, hemolytic anemia, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, psoriasis, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroma, spondyloarthropathy, thyroiditis, vasculitis, vitiligo, myxedema, pernicious anemia and ulcerative colitis. In some embodiments, the inflammation is related to a bone marrow transplantation. In some embodiments, the inflammation is related to allograft rejection following tissue transplantation. In some embodiments, the condition associatedwith inflammation (or inflammatory condition) comprises a symptom and / or sequelae of myocardial infarction, or heart failure. In some embodiments, the inflammatory condition comprises a cardiac inflammatory condition. In some embodiments, the condition associated with inflammation (or inflammatory condition) comprises inflammation and / or fibrosis of the heart. In some embodiments, the condition associated with inflammation (or inflammatory condition) is a symptom and / or sequelae of myocardial infarction or heart failure (e.g., reduced heart function, cardiac tissue fibrosis, etc.). In some embodiments the hyperinflammatory response is due to a cytokine storm or the activation of multiple inflammatory pathways.
[0134] In some embodiments, the subject is a human subject. In some embodiments, the subject is a non-human subject, e.g., a non-human mammal.
[0135] A treatment method of the present disclosure can include administering to a subject in need of treatment a therapeutically effective amount of the nucleic acid of the present disclosure (or a composition containing the same, as described herein) to thereby treat the subject. In some embodiments, a method of treating a condition associated with inflammation and / or fibrosis includes administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a therapeutically effective amount of the nucleic acid of the present disclosure (or a composition containing the same, as described herein), thereby treating the condition associated with inflammation and / or fibrosis. In some embodiments, the method includes identifying a subject having or diagnosed with inflammation and / or fibrosis of the heart, as described herein, and administering a therapeutically effective amount of the nucleic acid of the present disclosure to the subject. In some embodiments, the subject is a subject who has or has suffered heart failure. In some embodiments, the subject is a subject who has or has suffered myocardial infarction. In some embodiments, the subject is a subject who has or has suffered acute myocardial infarction. In some embodiments, the subject is at risk of having heart failure and / or myocardial infarction (e.g., acute myocardial infarction).
[0136] In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject who has suffered myocardial infarction reduces a size of an infarct compared to a suitable reference (e.g., compared to the average infarct size in a cohort of patients who have suffered a similar myocardial infarction and were not treated by the methods herein). In some embodiments, administering the therapeutically effective amount ofthe nucleic acid to the subject who has suffered myocardial infarction reduces a size of an infarct by, by about, or by at least 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, or 70% or more compared to a suitable reference (e.g., compared to the average infarct size in a cohort of patients who have suffered a similar myocardial infarction and were not treated by the methods herein), optionally wherein the size of the infarct is reduced by a percentage in a range defined by any two of the preceding values (e.g., 5-70%, 10-60%, 15-50%, 15-30%, etc.). In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject who has suffered myocardial infarction reduces a level of circulating cardiac troponin I (cTNI) compared to a suitable reference (e.g., compared to the average level of cTNI in a cohort of patients who have suffered a similar myocardial infarction and were not treated by the methods herein, or compared to the level of cTNI in the subject before the administering). In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject who has suffered myocardial infarction reduces a level of cTNI by, by about, or by at least 10, 20, 30, 40, 50, 60, 70, 80, 85, 90, 95, 96, 97, 98, 99% or more compared to a suitable reference (e.g., compared to the average level of cTNI in a cohort of patients who have suffered a similar myocardial infarction and were not treated by the methods herein, or compared to the level of cTNI in the subject before the administering), optionally wherein the level of cTNI is reduced by a percentage in a range defined by any two of the preceding values (e.g., 10-99%, 10-90%, 30-60%, 50-80%, 60-85%, etc.). In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject who has suffered myocardial infarction improves a cardiac function compared to a suitable reference (e.g., compared to the cardiac function in a cohort of patients who have suffered a similar myocardial infarction and were not treated by the methods herein, or compared to the cardiac function in the subject before the administering). In some embodiments, the cardiac function is or includes ejection fraction or ventricular ejection fraction.
[0137] In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject alters the composition of macrophage subtypes in a muscle tissue, e.g., in skeletal muscle or cardiac muscle. In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject increases the number and / or abundance of CD68+ / CD206+ cells in a muscle tissue, e.g., skeletal muscle, compared to a suitable reference (e.g., before the administering, other subjects treated with a scrambleoligonucleotide, etc.). In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject increases the number and / or abundance of CD68+ / CD206+ cells in a muscle tissue, e.g., skeletal muscle, by, by about, or by at least 1.1, 1.2, 1.3, 1.4, 1.5, 2, 2.2, 2.5, 3, 3.5, 4, 4.5, 5 fold, or by a fold amount in a range defined by any two of the preceding values (e.g., 1.1-5 fold, 1.5-4.5 fold, 2-4 fold, 1.2-5 fold, etc.), compared to a suitable reference (e.g., before the administering, other subjects treated with a scramble oligonucleotide, etc.). In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject increases the number and / or abundance of CD68+ / CD206+ cells in a muscle tissue, e.g., skeletal muscle, compared to a suitable control. In some embodiments, the number and / or abundance of CD68+ / CD206+ cells in a muscle tissue, e.g., in skeletal muscle or cardiac muscle, is determined relative to the number and / or abundance of CD68+ / CD206- cells in the same tissue. In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject reduces the number and / or abundance of CD68+ / CD206+ cells in a muscle tissue, e.g., cardiac muscle, compared to a suitable reference (e.g., before the administering, other subjects treated with a scramble oligonucleotide, etc.). In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject reduces the number and / or abundance of CD68+ / CD206+ cells in a muscle tissue, e.g., cardiac muscle, by, by about, or by at least 0.1, 0.2, 0.3, 0.4 or 0.5 fold, or by a fold amount in a range defined by any two of the preceding values (e.g., 0.1-0.5 fold, 0.1-0.4 fold, 0.2-0.4 fold, 0.1-0.3 fold, etc ), compared to a suitable reference (e.g., before the administering, other subjects treated with a scramble oligonucleotide). In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject reduces the number and / or abundance of CD68+ / CD206+ cells in a muscle tissue, e.g., cardiac muscle, compared to a suitable control. In some embodiments, administering the therapeutically effective amount of the nucleic acid to the subject does not alter the number and / or abundance of CD68+ / C80+ cells in a muscle tissue, e.g., in skeletal muscle or cardiac muscle. In some embodiments, the number and / or abundance of CD68+ / CD80+ cells in a muscle tissue, e.g., in skeletal muscle or cardiac muscle, is determined relative to the number and / or abundance of CD68+ / CD80- cells in the same tissue.
[0138] In some embodiments, the method includes identifying a subject having or diagnosed with heart failure, or a symptom or sequelae thereof, as described herein, andadministering a therapeutically effective amount of the nucleic acid of the present disclosure to the subject. In some embodiments, the method includes identifying a subject who is at risk of, or has suffered myocardial infarction, or a symptom or sequelae thereof, as described herein, and administering a therapeutically effective amount of the nucleic acid of the present disclosure to the subject. In some embodiments, the method includes identifying a subject who is at risk of, or has suffered acute myocardial infarction, or a symptom or sequelae thereof, as described herein, and administering a therapeutically effective amount of the nucleic acid of the present disclosure to the subject.
[0139] Also provided herein is an extracellular vesicle (EV)-free method of treating a condition associated with inflammation and / or fibrosis. In some embodiments, the method includes administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a composition as described herein, comprising a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of noncoding RNA (ncRNA) (e.g., a PlWI-interacting RNA (piRNA)) in EVs from induced pluripotent stem cells (iPSC-EVs). In some embodiments, the ncRNA (e.g., piRNA) in EVs from iPSC-EVs is enriched in the EVs. In some embodiments, the ncRNA (e.g., piRNA) is enriched in EVs from iPSC-EVs compared to the abundance of the ncRNA (e.g., piRNA) in a non-therapeutic EV (e.g., EV isolated from a non-therapeutic cell type, such as but not limited to normal human dermal fibroblasts (NHDF)). In some embodiments, the ncRNA (e.g., piRNA) is enriched in iPSC-EV relative to EV from NHDF by, by about or by at least 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.5, 3, 4, 5, 10, 20, 30, 40, 50, 100, 200, 500, or 1000 fold, or optionally it is enriched by a fold amount in a range defined by any two or the preceding values (e.g., 1.1-1000 fold, 5-100 fold, 10-1000 fold, 2-200 fold, 1.1-5 fold, 1.2-4 fold, 1.5-3 fold, 1.8-2 fold, etc.). In some embodiments, the ncRNA (e.g., piRNA) is enriched in iPSC-EV relative to EV from NHDF by at least 2 fold. In some embodiments, the ncRNA (e.g., piRNA) is enriched in iPSC-EV relative to EV from NHDF by at least 10 fold. In some embodiments, the ncRNA (e.g., piRNA) is enriched in iPSC-EV relative to EV from NHDF by at least 100 fold.
[0140] In some embodiments, the method includes administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a composition as described herein, comprising a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of a ncRNA (e.g., PlWI-i nt erecting RNA (piRNA)) in EVsfrom induced pluripotent stem cells (iPSC-EVs), or a sequence having (i) no more than 3 substitutions thereto, and / or (ii) a truncation of no more than 10 nucleotides and a pharmaceutically acceptable excipient, wherein the composition is an EV-free composition. In some embodiments, the nucleic acid is RNA. In some embodiments, the isolated nucleic acid includes the nucleotide sequence of the ncRNA (e.g., piRNA) with a truncation of no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the 5’ end. In some embodiments, the isolated nucleic acid includes the nucleotide sequence of the ncRNA (e.g., piRNA) with a truncation of no more than 5 nucleotides from the 5’ end. In some embodiments, the isolated nucleic acid includes the nucleotide sequence of the ncRNA (e.g., piRNA) with a truncation of 1, 2, 3, 4, or 5 nucleotides from the 5’ end. In some embodiments, the isolated nucleic acid includes the nucleotide sequence of the ncRNA (e.g., piRNA) with a truncation of no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides from the 3’ end. In some embodiments, the isolated nucleic acid includes the nucleotide sequence of the ncRNA (e.g., piRNA) with a truncation of no more than 5 nucleotides from the 3’ end. In some embodiments, the isolated nucleic acid includes the nucleotide sequence of the ncRNA (e.g., piRNA) with a truncation of 1, 2, 3, 4, or 5 nucleotides from the 3’ end. In some embodiments, the isolated nucleic acid includes the nucleotide sequence of the ncRNA (e.g., piRNA) with 1, 2, or 3 substitutions. In some embodiments, the isolated nucleic acid includes the nucleotide sequence of the ncRNA (e.g., piRNA) with 1 substitution. In some embodiments, the isolated nucleic acid includes the nucleotide sequence of the ncRNA (e.g., piRNA) with a truncation of no more than 5 nucleotides from the 5’ end and with 1, 2, or 3 substitutions. In some embodiments, the isolated nucleic acid includes the nucleotide sequence of the ncRNA (e.g., piRNA) with a truncation of no more than 5 nucleotides from the 3’ end and with 1, 2, or 3 substitutions. In some embodiments, the isolated nucleic acid includes one or more chemically modified nucleotides, e.g., within the nucleotide sequence of the ncRNA (e.g., piRNA), or a variant thereof. In some embodiments, the one or more chemically modified nucleotides is a locked nucleic acid (LNA), and / or the nucleic acid comprises a phosphorothioate bond between at least one pair of consecutive nucleic acid residues.
[0141] In some embodiments, the method includes administering to the subject a therapeutically effective amount of the isolated nucleic acid comprising a nucleotide sequence of 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1). In someembodiments, the method includes administering to the subject a therapeutically effective amount of the isolated nucleic acid comprising a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2), wherein K is G or U, or a sequence having no more than 3 substitutions thereto. In some embodiments, the method includes administering to the subject a therapeutically effective amount of any one or more of the isolated nucleic acid comprising a nucleotide sequence selected from: 5’- AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:3), 5’- GCCCGGCUAGCUCAGUCGGUAGAGCAUGAGAC-3’ (SEQ ID NO:4), 5’- GGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 5), 5’- AUUGGUGGUUCAGUGGUAGAAUUCUCGCCUG-3’ (SEQ ID NO:6) and 5’-UUGGUGGUUCAGUGGUAGAAUUCUCGCCUGCC-3’ (SEQ ID NO:7). In some embodiments, the method includes administering to the subject a therapeutically effective amount of the isolated nucleic acid comprising a nucleotide sequence of: 5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:3). In some embodiments, the method includes administering to the subject a therapeutically effective amount of the isolated nucleic acid comprising a nucleotide sequence of: 5’-GCCCGGCUAGCUCAGUCGGUAGAGCAUGAGAC-3’ (SEQ ID NO:4). In some embodiments, the method includes administering to the subject a therapeutically effective amount of the isolated nucleic acid comprising a nucleotide sequence of 5’-GGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 5). In some embodiments, the method includes administering to the subject a therapeutically effective amount of the isolated nucleic acid comprising a nucleotide sequence of: 5’-AUUGGUGGUUCAGUGGUAGAAUUCUCGCCUG-3’ (SEQ ID NO: 6). In some embodiments, the method includes administering to the subject a therapeutically effective amount of the isolated nucleic acid comprising a nucleotide sequence of: 5’-UUGGUGGUUCAGUGGUAGAAUUCUCGCCUGCC-3’ (SEQ ID NO:7). In some embodiments, the method includes administering to the subject a therapeutically effective amount of the isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is G or C (SEQ ID NO: 33). In some embodiments, the method includes administering to the subject a therapeutically effective amount of the isolated nucleic acid comprising a nucleotide sequence of: 5’-SGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 32), wherein S is G or C, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 27 nucleotides long.
[0142] In some embodiments, conditions treated by the present treatment methods are associated with inflammation and / or fibrosis of the heart or skeletal muscle. In some embodiments, the conditions treated by the present treatment methods are a symptom and / or sequelae of heart failure or myocardial infarction. In some embodiments, the condition treated by the present treatment methods is ischemic cardiac muscle injury.
[0143] The nucleic acid or composition can be administered using any suitable route. Administration can be local or systemic. In some embodiments, administration is parenteral. Suitable option for administration include, without limitation, intravenous, intramuscular, subcutaneous, intra-arterial, intraperitoneal, or oral administration.
[0144] The nucleic acid or composition can be administered to the subject at any suitable amount. In some embodiments, the therapeutically effective amount of the nucleic acid is in a range of 0.01 pg-10 mg. In some embodiments, the therapeutically effective amount of the nucleic acid is in a range of 0.001 mg / kg-10 mg / kg. In some embodiments, the therapeutically effective amount of the nucleic acid is or is about 5 mg / kg. The nucleic acid or composition can be administered to the subject at any suitable dosing schedule or dosing frequency. The nucleic acid or composition can be administered to the subject any suitable number of times. In some embodiments, the nucleic acid or composition is administered to the subject at regular intervals. In some embodiments, the nucleic acid or composition is administered to the subject chronically.
[0145] Also provided is a method of immunomodulation (“immunomodulation method”) comprising contacting an effective amount of the nucleic acid of the present disclosure (or a composition containing the same, as described herein), with a population of macrophages, e.g., human macrophages. In some embodiments, the contacting comprises administering to a subject in need of treating a condition associated with inflammation and / or fibrosis the effective amount of the isolated nucleic acid. In some embodiments, the contacting is done in vitro, for example, in culture. In some embodiments, the macrophage is a human macrophage.
[0146] In some embodiments, contacting the effective amount of the isolated nucleic acid or composition of the present disclosure with a population of macrophages (e.g.,a population of activated macrophages) reduces expression or production of one or more inflammatory (e.g., pro-inflammatory) cytokines, compared to a suitable reference (e.g., a population of macrophages that have not been treated with the immunomodulation method). In some embodiments, production of a cytokine denotes release of the cytokine into the surrounding medium by the population of macrophages. In some embodiments, contacting the effective amount of the isolated nucleic acid or composition of the present disclosure with a population of activated macrophages reduces production of one or more pro-inflammatory cytokines, compared to a suitable reference (e.g., a population of activated macrophages that have not been treated with the immunomodulation method). In some embodiments, contacting the effective amount of the isolated nucleic acid or composition of the present disclosure with a population of activated macrophages reduces expression and / or production of IL-6, TNF-a, IL- 12, CCL3, CD40 and / or IFN-gamma, compared to a suitable reference (e.g., a population of activated macrophages that have not been treated with the immunomodulation method). In some embodiments, contacting the effective amount of the isolated nucleic acid or composition of the present disclosure with a population of macrophages reduces expression and / or production of IL-6, TNF-a, IL-12, CCL3, CD40 and / or IFN-gamma in the population of macrophages by, by about, or by at least 10, 20, 30, 40, 50, 60, 70, 75, or 80% or more, or optionally reduces expression and / or production by a percentage in a range defined by any two of the preceding values (e.g., 10-80%, 20-75%, 30-60%, 10-50%, etc.), compared to a suitable reference (e g., a population of activated macrophages that have not been treated with the immunomodulation method).
[0147] Also provided herein is a method of identifying candidate therapeutic nucleic acids (also referred to herein as “identification methods”). The method can include obtaining sequencing data of a plurality of nucleic acids from therapeutic extracellular vesicles (EV); identifying a candidate therapeutic nucleic acid based on: (a) an enrichment analysis of the sequencing data that has been annotated relative to a reference sequencing data of a plurality of nucleic acids from non-therapeutic EV, wherein the reference sequencing data has been annotated, wherein the enrichment analysis identifies a first sequence motif that is enriched in the sequencing data; and (b) a sequence-based quantification of abundance of the sequencing data that has not been annotated, wherein the sequence-based quantification identifies a second sequence motif that is enriched in the sequencing data, wherein a sequencehomology between the first sequence motif and the second sequence motif identifies a candidate therapeutic nucleic acid. In some embodiments, the nucleic acids are RNA. In some embodiments, the RNA are non-coding RNA. In some embodiments, the annotated sequencing data comprises annotation of one or more sequence in the sequencing data as one or more of piRNA, miRNA, and tRNA. In some embodiments, the annotated sequencing data comprises annotation of sequences in the sequencing data as piRNA, miRNA, or tRNA. In some embodiments, the identified candidate therapeutic nucleic acid is a piRNA. In some embodiments, the identified candidate therapeutic nucleic acid is a miRNA. In some embodiments, the identified candidate therapeutic nucleic acid includes a nucleotide sequence that is complementary to a sequence within an mRNA of one or more genes in the transcriptome (e.g., human transcriptome where the iPSC is a human iPSC).
[0148] Any suitable sequencing data of a plurality of nucleic acids from therapeutic EV can be used in the present identification methods. In some embodiments, the therapeutic EV are derived from induced pluripotent stem cells (iPSC). In some embodiments, the iPSC are human iPSC. In some embodiments, the iPSC are peripheral blood mononuclear cell (PBMC)-derived iPSC. In some embodiments, the therapeutic EV have therapeutic effect in treating inflammation and / or fibrosis of the heart or skeletal muscle, e.g., when the EV are administered to a subject in need thereof. In some embodiments, the therapeutic EV have therapeutic effect in treating a symptom and / or sequelae of heart failure or myocardial infarction. In some embodiments, the therapeutic EV have therapeutic effect in treating ischemic cardiac muscle injury. The sequencing data can be obtained from any suitable option. In some embodiments, the sequencing data is obtained from high-throughput sequencing or next generation sequencing, sequencing by synthesis, nanopore sequencing, Sanger sequencing, etc.
[0149] In some embodiments, the first sequence motif is comprised in one or more of the 100 most abundant sequences in the annotated sequencing data, and / or the second sequence motif is comprised in one or more of the 100 most abundant sequences in the unannotated sequencing data. In some embodiments, the first sequence motif is comprised in one or more of the 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 most abundant sequences in the annotated sequencing data, or optionally is comprised in one or more of the sequences having an abundance in a range defined by any twoof the preceding values (e.g., 10-1000 most abundant, 10-100 most abundant, 50-200 most abundant, 20-500 most abundant, etc.). In some embodiments, the second sequence motif is comprised in one or more of the 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 most abundant sequences in the un-annotated sequencing data, or optionally is comprised in one or more of the sequences having an abundance in a range defined by any two of the preceding values (e.g., 10-1000 most abundant, 10-100 most abundant, 50-200 most abundant, 20-500 most abundant, etc.).
[0150] In some embodiments, the method includes testing in vitro and / or in vivo a therapeutic effect of the identified candidate therapeutic nucleic acid comprising the first and second sequence motifs. In some embodiments, the in vitro and / or in vivo test recapitulates one or more of the therapeutic or biological effects of the therapeutic EV from which the candidate therapeutic nucleic acid was derived.KITS
[0151] Also provided herein are kits that include the isolated nucleic acid of the present disclosure. In some embodiments, the kit includes a pharmaceutically acceptable excipient. The present kit in some embodiments finds use in treating conditions that include, without limitation, inflammation and / or fibrosis of the heart or skeletal muscle, heart failure, myocardial infarction, and ischemic cardiac muscle injury. Kits can include one or more containers (e.g., vials, ampoules, test tubes, flasks or bottles) for holding one or more components of the kits. The kits may further include instructions for using the kit to treat a condition (e.g., heart failure, myocardial infarction, or an inflammatory condition associated therewith). The information and instructions may be in the form of words, pictures, or both, and the like.Additional Embodiments
[0152] Additional non-limiting embodiments of the present disclosure is provided by the following numbered embodiments.1. A method of treating a condition associated with inflammation and / or fibrosis, comprising administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1) or a sequence having no more than 3 substitutions thereto, wherein the nucleic acidis RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is, or is about 25 nucleotides long.la. A method of treating a condition associated with inflammation and / or fibrosis, comprising administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10) or a sequence having no more than 3 substitutions thereto, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is, or is about 25 nucleotides long.lb. The method of embodiment la, comprising a cytosine at position 1 of SEQ ID NOTO.lc. The method of embodiment la or lb, wherein the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is G or C (SEQ ID NO: 33), optionally wherein the isolated nucleic acid consists of or consists essentially of the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).2. The method of any one of the preceding embodiments, wherein the isolated nucleic acid comprises a nucleotide sequence of: 5’- GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NOT), wherein K is G or U, or a sequence having no more than 3 substitutions thereto.3. The method of any one of the preceding embodiments, wherein the isolated nucleic acid does not comprise: 5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NOT).4. The method of any one of the preceding embodiments, wherein the nucleic acid consists of or consists essentially of the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).4a. The method of any one of the preceding embodiments, wherein the isolated nucleic acid comprises at least one chemically modified nucleotide, optionally wherein the at least one chemically modified nucleotide comprises a backbone modification.5. An extracellular vesicle (EV)-free method of treating a condition associated with inflammation and / or fibrosis, comprising administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a composition comprising:a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of a noncoding RNA (e.g., PlWI-interacting RNA (piRNA)) in EVs from induced pluripotent stem cells (iPSC-EVs), or a sequence having (i) no more than 3 substitutions thereto, and / or (ii) a truncation of no more than 10 nucleotides thereof, wherein the nucleic acid is RNA, and wherein the nucleic acid is at most 35 nucleotides long; anda pharmaceutically acceptable excipient,wherein the composition is an EV-free composition, optionally wherein the piRNA is enriched in the iPSC-EVs.6. The method of embodiment 5, wherein the iPSC are human iPSC.7. The method of embodiment 5 or 6, wherein the iPSC are peripheral blood mononuclear cell (PBMC)-derived iPSC.8. The method of any one of embodiments 5-7, wherein the nucleotide sequence is selected from:5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:3);5’-GCCCGGCUAGCUCAGUCGGUAGAGCAUGAGAC-3’ (SEQ ID NO: 4); 5’-GGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 5);5’-AUUGGUGGUUCAGUGGUAGAAUUCUCGCCUG-3’ (SEQ ID NO: 6); or 5’-UUGGUGGUUCAGUGGUAGAAUUCUCGCCUGCC-3’ (SEQ ID NO: 7). 9. The method of any one of embodiments 5-8, wherein the isolated nucleic acid comprises a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1) or a sequence having no more than 3 substitutions thereto, optionally wherein the nucleotide sequence is 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).10. The method of any one of embodiments 5-9, wherein the isolated nucleic acid comprises a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2), wherein K is G or U, or a sequence having no more than 3 substitutions thereto.11. The method of any one of embodiments 5-9, wherein the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is G or C (SEQ ID NO: 33), optionally wherein the nucleic acid consists of or consists essentially of the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).12. The method of any one of the preceding embodiments, wherein the condition associated with inflammation and / or fibrosis comprises inflammation and / or fibrosis of the heart or skeletal muscle.13. The method of any one of the preceding embodiments, wherein the condition associated with inflammation and / or fibrosis comprises a symptom and / or sequelae of heart failure or myocardial infarction.14. The method of any one of the preceding embodiments, wherein the condition associated with inflammation and / or fibrosis comprises ischemic cardiac muscle injury.15. The method of any one of the preceding embodiments, comprising intravenously, intramuscularly, or intracardially administering the therapeutically effective amount of the nucleic acid to the subject.16. A method of immunomodulation, comprising contacting an effective amount of an isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1) with a population of macrophages, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is, or is about 25 nucleotides long.16a. A method of immunomodulation, comprising contacting an effective amount of an isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10) with a population of macrophages, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is, or is about 25 nucleotides long.16b. The method of embodiment 16a, wherein the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is G or C (SEQ ID NO: 33), optionally wherein the isolated nucleic acid consists of or consists essentially of the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).17. The method of embodiment 16, wherein the isolated nucleic acid comprises a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2), wherein K is G or U, or a sequence having no more than 3 substitutions thereto.18. The method of any one of embodiments 16, 16a, 16b, and 17, wherein the isolated nucleic acid does not comprise: 5’- AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 3).19. The method of any one of embodiments 16-18, wherein the nucleic acid consists of or consists essentially of the nucleotide sequence: 5’- GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).20. The method of any one of embodiments 16-19, wherein the contacting comprises administering to a subject in need of treating a condition associated with inflammation and / or fibrosis the effective amount of the isolated nucleic acid.21. The method of any one of embodiments 16-20, wherein the macrophage is a human macrophage.22. The method of any one of embodiments 16-19 and 21, wherein the contacting is done in vitro.23. The method of any one of embodiments 16-22, wherein contacting the effective amount of the isolated nucleic acid reduces expression of one or more pro-inflammatory cytokines in the population of macrophages, optionally wherein the one or more pro-inflammatory cytokines comprises one or more of: CD40, IL-6, or IL-12.24. The method of any one of the preceding embodiments, wherein the nucleic acid comprises at least one chemically modified nucleotide, optionally wherein the at least one chemically modified nucleotide is a locked nucleic acid (LNA) and / or wherein the nucleic acid comprises a phosphorothioate bond between at least one pair of nucleic acid residues that are adjacent each other in the nucleotide sequence.25. The method of embodiment 24, wherein the at least one chemically modified nucleotide comprises a backbone modification.26. The method of embodiment 25, wherein the backbone modification comprises a backbone sugar modification.26a. The method of any one of the preceding embodiments, wherein the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is Gor C (SEQ ID NO: 33), wherein at least one of positions 1, 3, 5, 21, 23, and 25 of SEQ ID NOG 3 comprises a chemically modified nucleotide, optionally wherein the chemically modified nucleotide is a locked nucleic acid (LNA).26b. The method of embodiment 26a, wherein each of positions 1, 3, 5, 21, 23, and 25 of SEQ ID NO: 33 comprises a LNA, optionally wherein the nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 15), wherein each oppositions 1, 3, 5, 21, 23, and 25 of SEQ ID NO: 15 comprises a LNA.27. An isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long or at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long.27a. An isolated nucleic acid comprising a nucleotide sequence of: 5’-SGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10), wherein S is G or C, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long, further optionally wherein the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11), or 5’-CGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 12).28. An isolated nucleic acid comprising a nucleotide sequence at least 95% identical to 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), wherein the nucleic acid is RNA, wherein the isolated nucleic acid is at most 35 nucleotides long or at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long.28a. An isolated nucleic acid comprising a nucleotide sequence at least 95% identical to 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10), wherein the nucleic acid is RNA, wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long, further optionally wherein the nucleotide sequence is at least 95% identical to 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).28b. The isolated nucleic acid of embodiment 28a, comprising a cytosine at position 1 of SEQ ID NO: 10.28c. The isolated nucleic acid of embodiment 28a or 28b, wherein the nucleotide sequence is at least 95% identical to 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is G or C (SEQ ID NO: 33).29. The isolated nucleic acid of any one of embodiments 27-28c, comprising a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2) , wherein K is G or U, or a sequence having no more than 3 substitutions thereto.30. The isolated nucleic acid of any one of embodiments 27-29, that does not comprise: 5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ IDNO:3).31. The isolated nucleic acid of any one of embodiments 27-30, consisting of or consisting essentially of the nucleotide sequence: 5’- GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).32. The isolated nucleic acid of any one of embodiments 27-31, wherein the nucleic acid comprises at least one chemically modified nucleotide, optionally wherein the at least one chemically modified nucleotide is a locked nucleic acid (LNA) and / or wherein the nucleic acid comprises a phosphorothioate bond between at least one pair of consecutive nucleic acid residues.33. The isolated nucleic acid of embodiment 32, wherein the at least one chemically modified nucleotide comprises a backbone modification.34. The isolated nucleic acid of embodiment 33, wherein the backbone modification comprises a backbone sugar modification.34a. The isolated nucleic acid of any one of embodiments 32-34, wherein the nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11), wherein at least one of positions 1, 3, 5, 21, 23, and 25 of SEQ ID NO: 11 comprises a chemically modified nucleotide, optionally wherein the chemically modified nucleotide is a locked nucleic acid (LNA).34b. The isolated nucleic acid of any one of embodiments 32-34a, wherein the nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 15), wherein each of positions 1, 3, 5, 21, 23, and 25 of SEQ ID NO: 15 comprises a LNA.35. The isolated nucleic acid of any one of embodiments 27-34, wherein the nucleic acid consists of or consists essentially of the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).35a. An isolated nucleic acid comprising one of the following nucleotide sequences, or a sequence at least 95% identical to:(a) 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:1), wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long;(b) 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO:10), wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 22 nucleotides long;(c) 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11), wherein the isolated nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long; or(d) 5’-CGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 12), wherein the isolated nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long.35b. The isolated nucleic acid of embodiment 35a, comprising at least one chemically modified nucleotide, optionally wherein the chemically modified nucleotide comprises a locked nucleic acid (LNA) and / or wherein the nucleic acid comprises a phosphorothioate bond between at least one pair of consecutive nucleic acid residues.35c. The isolated nucleic acid of embodiment 35b, comprising any one of SEQ ID NOs: 1, 11, and 12, wherein the nucleic acid is 25 nucleotides long, and wherein each of positions 1, 3, 5, 21, 23, and 25 of the nucleic acid sequence comprises the LNA.36. The isolated nucleic acid of any one of embodiments 27-35c for use in the treatment of:(a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or(b) ischemic cardiac muscle injury; or(c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition.37. The isolated nucleic acid of any one of embodiments 27-35 for use in the preparation of a medicament for the treatment of:(a) a condition associated with inflammation and / or fibrosis, optionally wherein the condition comprises inflammation and / or fibrosis of the heart muscle; or(b) ischemic cardiac muscle injury; or(c) a muscle disorder or a symptom thereof, optionally wherein the muscle disorder comprises a heart condition.38. The isolated nucleic acid for use of embodiment 36 or 37, wherein the heart condition comprises a symptom and / or sequelae of heart failure.39. A kit compri si ng :the isolated nucleic acid of any one of embodiments 27-35; anda pharmaceutically acceptable excipient.40. A method of identifying candidate therapeutic nucleic acids, comprising: obtaining sequencing data of a plurality of nucleic acids from therapeutic extracellular vesicles (EV);identifying a candidate therapeutic nucleic acid based on:(a) an enrichment analysis of the sequencing data that has been annotated relative to a reference sequencing data of a plurality of nucleic acids from non-therapeutic EV, wherein the reference sequencing data has been annotated, wherein the enrichment analysis identifies a first sequence motif that is enriched in the sequencing data; and(b) a sequence-based quantification of abundance of the sequencing data that has not been annotated, wherein the sequence-based quantification identifies a second sequence motif that is enriched in the sequencing data,wherein a sequence homology between the first sequence motif and the second sequence motif identifies a candidate therapeutic nucleic acid,optionally wherein the annotated sequencing data comprises annotation for one or more of piRNA, miRNA, and tRNA.41. The method of embodiment 40, wherein the nucleic acids are RNA, optionally wherein the RNA are non-coding RNA.42. The method of embodiment 40 or 41, wherein the therapeutic EV are derived from induced pluripotent stem cells (iPSC), optionally wherein the iPSC are human iPSC, further optionally wherein the iPSC are peripheral blood mononuclear cell (PBMC)-derived iPSC.43. The method of any one of embodiments 40-42, wherein the first sequence motif is comprised in one or more of the 100 most abundant sequences in the annotated sequencing data, and / or the second sequence motif is comprised in one or more of the 100 most abundant sequences in the un-annotated sequencing data.44. The method of any one of embodiments 40-43, comprising testing in vitro and / or in vivo a therapeutic effect of the identified candidate therapeutic nucleic acid comprising the first and second sequence motifs.
[0153] All patents and other publications; including literature references, issued patents, published patent applications, and co-pending patent applications; cited throughout this application are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodologies described in such publications that might be used in connection with the technology described herein. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents.
[0154] The description of embodiments of the disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. While specific embodiments of, and examples for, the disclosure are described herein for illustrative purposes, various equivalent modifications are possible within the scope of the disclosure, as those skilled in the relevant art will recognize. For example, while method steps or functions are presented in a given order, alternative embodiments may perform functions in a different order, or functions may be performed substantially concurrently. The teachings of the disclosure provided herein can be applied to other procedures or methods as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the disclosure can be modified, if necessary, to employ the compositions, functions and concepts of the above references and application to provide yet further embodiments of the disclosure. Moreover, due to biological functional equivalency considerations, some changes can be made in protein or nucleic acid structure without affecting the biological or chemical action in kind or amount. These and other changes can be made to the disclosure in light of the detailed description. All such modifications are intended to be included within the scope of the appended claims.
[0155] Specific elements of any of the foregoing embodiments can be combined or substituted for elements in other embodiments. Furthermore, while advantages associated withcertain embodiments of the disclosure have been described in the context of these embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages to fall within the scope of the disclosure.
[0156] The technology described herein is further illustrated by the following examples, which in no way should be construed as being further limiting.EXAMPLESMethods
[0157] All experiments were performed in accordance with relevant guidelines and ethical regulations approved by Cedars-Sinai Medical Center. All animal work was performed according to protocols approved by the IACUC at Cedars-Sinai Medical Center (IACUC 009183) and NIH Guide for the Care and Use of Laboratory Animals.Generation of human iPSCs and isolation of iPSC-EVs
[0158] To establish a foundation for EV production, the Cedars-Sinai Biomanufacturing Center, led by Dr. Dhruv Sareen, reprogrammed peripheral blood mononuclear cells (PBMCs) from two healthy human donors (one male, one female) using episomal vectors encoding the Yamanaka factors (Oct3 / 4, Sox2, KLF4, L-Myc, shp53, Lin28). The two validated iPSC lines were cultured in serum-free conditions (to avoid differentiation) and collected conditioned media every 48 hours for EV isolation. From the conditioning media, EVs were purified using differential ultracentrifugation (100,000 x g for 70 mins), after sequential centrifugations at 300 x g (10 min) and 10,000 x (30 min) and filtration with 0.22 pm filters. Isolated exosomes were re-suspended in PBS (for in vivo and in vitro experiments).Mouse model of MI and therapeutics injection procedure
[0159] Male C57BL / 6 mice (8-10 weeks) from the Jackson Laboratory were used for all animal studies. Male mice were chosen because they are known to exhibit more severe manifestations of MI than female mice, including worse survival, functional recovery, and remodeling. A mouse MI model was made according to our previous work. Briefly, MI was induced via a left parasternal thoracotomy performed under anesthesia. A ligature was tightened around the left anterior descending coronary artery for 45 minutes of ischemia and then released to allow reperfusion. Twenty minutes later, an intravenous (i.v.) injection of 100 pL of each test item (iPSC-EVs from different donors, 2 x 109EVs / mouse) or vehicle (PBS) was administered. For RNA treatment, vehicle (PBS with DharmaFECT®), mREXl, or Scr(at 5 mg / kg, formulated in DharmaFECT® as previous studies) was injected into the retro-orbital sinus.2,3,5-Triphenyl-2H-tetrazolium chloride staining
[0160] Two days post -MI, mice were euthanized and 10% KC1 was injected into the LV to arrest hearts in diastole. Then, hearts were harvested, washed in PBS, and cut into 1 mm sections from apex to base. Sections were incubated with 1% 2,3,5-triphenyl-2H-tetrazolium chloride (TTC) (Sigma-Aldrich) solution for 30 min at 37°C in the dark and washed with PBS. Then, heart sections were imaged. And the infarcted zones (white) were delineated from viable tissue (red) and analyzed (ImageJ software).Cardiac Troponin I enzyme-linked immunosorbent assay
[0161] Blood was collected from all animals at the study endpoint in ethylenediaminetetraacetic acid (EDTA) tubes. Plasma was obtained after 15 min centrifugation at 3000 g. Cardiac Tnl was quantified using the Mouse cardiac Troponin I enzyme-linked immunosorbent assay (ELISA) kit (Life Diagnostics), according to the manufacturer’s protocol.In vitro bone marrow derived macrophage (BMDM) study
[0162] Briefly, monocytes were harvested from mouse bone marrow in femurs and cultured in media containing M-CSF for 7 days, to yield BMDM. Macrophages were first stimulated with lipopolysaccharide (LPS) to induce a pro-inflammatory response, followed by treatment with iPSC-EVs from each of the two human lines (EV-1 and EV-2). Four groups were compared: Control (no LPS); Vehicle (LPS + Phosphate-Buffered Saline (PBS) only); EV-1 (LPS + EV-1); EV-2 (LPS + EV-2).Small RNA sequencing on iPSC-EVs
[0163] Small RNA preparation and sequencing. Total RNA, including small RNAs, was extracted from iPSC-EVs and NHDF-EVs using the Qiagen miRNeasy Micro Kit, following the manufacturer’s protocol. Samples were eluted in RNase-free water and stored at -80 °C. NHDF-EVs were isolated using the same protocol as described above for iPSC-EVs to ensure consistency. RNA yield and integrity were assessed using the Agilent Bioanalyzer. Samples displaying enrichment in small RNA range and minimal degradation were selected for sequencing. Small RNA libraries were generated using the NEBNext® Small RNA Library Prep Set for Illumina (NEB, Cat# E7330S). Each library was indexed for multiplex sequencingand amplified by 12-15 PCR cycles. Libraries were sequenced as 50 bp single-end reads on an Illumina NovaSeq 6000 platform at the Cedars-Sinai Genomics Core, targeting a depth of 20 million reads per sample. Six independent iPSC-EV preparations from each donor were sequenced (n=6).
[0164] Data processing. Raw fastq files were trimmed using CLC Genomics Workbench software to remove adapter sequences, and filtered for quality using FastQC. Clean reads were aligned to the GRCh38 / hg38 human genome using STAR (v2.7) or Bowtie, depending on the RNA type. Reads were annotated using miRBase (miRNAs), piRNABank (piRNAs), GtRNAdb (tRNAs), and Ensembl (for IncRNAs and others). Gene-level quantification was performed using featureCounts. Normalization and statistical analysis were conducted using DESeq2 in R. Differentially enriched RNAs were defined as those with an adjusted p-value < 0.05 and log2 fold-change > 1.5.
[0165] Comparative analysis. Only RNAs with consistent enrichment across all replicates and at least 2-fold upregulation in iPSC-EVs vs. NHDF-EVs were considered. Identified RNAs were queried via PubMed to assess known or suspected roles in inflammation, macrophage modulation, immune signaling, and cardiac repair.Statistical analysis
[0166] All experiments were performed independently at least three times. Results are shown as means ± standard deviation (SD). Comparisons between any two groups were performed using the two-tailed, unpaired Student’s t test. Comparisons between more than two groups were performed using the one-way analysis of variance (ANOVA), followed by Tukey's honestly significant difference (HSD) post hoc test. For the analysis of variance with two factors, two-way ANOVA was used and followed by Holm-Sidak post hoc test, and P < 0.05 was considered statistically significant.Example 1
[0167] This non-limiting example summarizes Examples 2-12.
[0168] Myocardial infarction (MI) is a leading cause of heart failure, and current therapies cannot reverse the damage caused by the heart’s limited regenerative capacity. Although human induced pluripotent stem cells (iPSCs) hold promise for regenerative medicine, clinical translation is hindered by risks such as genomic instability, tumorigenicity,and immunogenicity. This study investigates the therapeutic potential and underlying mechanisms of extracellular vesicles (EVs) derived from iPSCs as a cell-free strategy for cardiac repair. EVs were isolated from iPSC-conditioned media using ultracentrifugation and characterized by nanoparticle tracking analysis and surface markers (e.g., CD63). Bioactivity was assessed through an in vitro macrophage assay and an in vivo mouse model of acute MI. In vitro, iPSC-EVs reduced pro-inflammatory cytokine production in macrophages. In vivo, EV-treated mice exhibited reduced infarct sizes and lower cardiac troponin I levels, indicating improved cardiac recovery. Immunofluorescence revealed increased CD206+macrophages in EV-treated hearts, consistent with enhanced M2 anti-inflammatory polarization. These findings suggest that iPSC-EVs promote cardiac repair by modulating post-infarction immune responses.
[0169] The RNA cargo in iPSC-EVs that mediate macrophage polarization and tissue repair can be identified.Example 2
[0170] This non-limiting example shows isolation and characterization of EVs from two iPSC cell lines.
[0171] To produce extracellular vesicles (EVs), peripheral blood mononuclear cells (PBMCs) from two healthy human donors (one male, one female) were reprogrammed using episomal vectors encoding the Yamanaka factors (Oct3 / 4, Sox2, KLF4, L-Myc, shp53, Lin28) (FIG. 1A). Immunofluorescence staining was performed on the EVs to confirm the expression of key pluripotency markers (such as Oct4, Sox2, Nanog) in both lines. Figure IB shows representative images of the immunofluorescence staining of Oct4, Sox2, Nanog, demonstrating successful reprogramming and maintenance of a pluripotent state of the PBMCs. Both cell lines displayed typical colony morphology and maintained stable growth in feeder-free, xeno-free culture conditions.
[0172] The two iPSC lines were cultured in serum-free conditions (to avoid differentiation) and collected in the conditioned media every 48 hours for EV isolation. From the conditioned media, the EVs were purified using differential ultracentrifugation (FIG. 2 A).
[0173] FIGs. 2A-2C: Characterization of iPSC-EVs from two donors. FIG. 2A: Schematic of ultracentrifugation method. FIG. 2B: Size distribution of iPSC-EVs measured byNanosight Analysis. FIG. 2C: Representative images showing the expression of surface markers in iPSCs.
[0174] Nanoparticle tracking analysis (NTA) was performed to confirm that both preparations contained small EVs with a size distribution centered around 100-150 nm, typical of exosomes (FIG. 2B). The expression of canonical EV markers (CD63, Alix, TSG101) on the purified iPSC-EVs was verified by immunoblotting (FIG. 2C). This confirmed successful isolation of the EVs and both the donor lines had comparable EV production. In addition, the absence of Calnexin, an ER-associated protein, validated the purity of the EV preparations and minimized concerns about contamination from cellular debris.Example 3
[0175] This non-limiting example shows potential bioactivity of iPSC-EVs in an in vitro macrophage model.
[0176] EV-derived noncoding RNAs can be taken up by macrophages and affect various biological processes related to innate immunity. Bone marrow-derived macrophage (BMDM) model was used to assess the immunomodulatory capacity of iPSC-EVs. Monocytes were harvested from mouse bone marrow in femurs and cultured in media containing M-CSF for 7 days, to yield BMDMs. Macrophages were first stimulated with lipopolysaccharide (LPS) to induce a proinflammatory response, followed by treatment with iPSC-EVs from each of the two human lines (EV-1 and EV-2).
[0177] Four groups were compared: Control (no LPS); Vehicle (LPS + Phosphate-Buffered Saline (PBS) only); EV-1 (LPS + EV-1); EV-2 (LPS + EV-2). Cytokine array analysis of total proteins released by macrophages showed higher levels of multiple pro-inflammatory cytokines (including IL-6, TNF-a, IL- 12, CCL3, CD40 and IFN-gamma) in Vehicle group, but a marked reduction of those cytokines after EV treatment (FIG. 3A).
[0178] FIGs. 3A-3G: Modulation effects of iPSC-EVs on mouse macrophages in vitro. FIG. 3A: Cytokine array analysis of proteins released by macrophages treated with EVs or vehicle. FIG. 3B: Quantitative analysis of CD40 regulated by EV treatment. FIG. 3C: Quantitative analysis of IFN-gamma regulated by EV treatment. FIG. 3D: Quantitative analysis of IL-6 regulated by EV treatment. FIG. 3E: Quantitative analysis of IL-12 regulated by EV treatment. FIG. 3F: Quantitative analysis of CCL3 regulated by EV treatment. FIG.3G: Quantitative analysis of TNF-a regulated by EV treatment.
[0179] Quantitative analysis of pooled data of major cytokines that are significantly regulated by the EV treatment showed significant suppression of several key cytokines such as IL-6a and IL- 12 cross both donor-derived EV preparations, demonstrating conserved bioactivity (FIGs. 3B-3G). Thus, iPSC-EVs suppress the inflammatory activation of macrophages.
[0180] In the context of tissue injury, macrophages play a central role in coordinating the immune response, with Ml -like macrophages promoting inflammation and M2 -like macrophages supporting resolution and repair. The observed cytokine changes are consistent with a shift toward an M2-like reparative phenotype induced by iPSC-EVs. This capacity to modulate macrophage polarization is particularly relevant to MI, in which excessive or prolonged Ml activation is known to contribute to maladaptive post-MI structural dilatation and wall thinning known collectively as adverse remodeling.
[0181] These in vitro results show that iPSC-EVs can mediate anti-inflammatory effects and can regulate immune cell responses relevant to post-MI healing.Example 4
[0182] This non-limiting example shows bioactivity of iPSC-EVs in an in vivo mouse model of MI.
[0183] In the mouse model of MI induced by ischemia / reperfusion (I / R) was used to evaluate the therapeutic potential of iPSC-EVs. Eight- to ten-week-old C57BL / 6J mice underwent left coronary artery ligation for 45 minutes followed by reperfusion to mimic the clinical setting of acute MI (FIG. 4A). Mice were randomized into four groups (n = 3 ~5 ) : Sham (surgery without ligation), Vehicle (I / R + PBS only); EV-1 (I / R + EV-1); EV-2 (I / R + EV-2). Twenty minutes after reperfusion, mice in the treatment groups received a single intravenous dose of PBS (100 pL) or iPSC-EVs (2 x 1O10particles per mouse in 100 pL PBS) via retro-orbital injection. Two days post-MI, mice were sacrificed for acute endpoint analyses of harvested blood and heart.
[0184] FIGs. 4A-4D: Efficacy of iPSC-EVs in a mouse model of I / R. FIG. 4A: Schematic showing the timeline of mouse I / R model. FIG. 4B: Representative images from TTC staining showing the infarct area in mice heart after vehicle or EV injection. FIG. 4C: Quantitative analysis of infarct area. FIG. 4D: Quantification of cTNI level in mouse serum. n= 3-5.
[0185] Infarct size was measured using TTC staining of heart slices, and circulating cardiac troponin I (cTnl), an ischemic biomarker used clinically, was assessed by ELISA. iPSC-EV-treated mice showed significantly smaller infarct sizes compared to vehicle controls (FIGs. 4B-4C), along with markedly reduced serum cTnl levels (FIG. 4D), indicating effective cardioprotection. These findings provide in vivo evidence that iPSC-EVs confer early cardioprotection following MI injury.Example 5
[0186] This non-limiting example shows small RNA profiling of iPSC-EVs.
[0187] Small RNA sequencing was performed on pilot-scale EV batches derived from both donor iPSC lines to explore the molecular mechanisms underlying iPSC-EV bioactivity. Total RNA was extracted using the Qiagen miRNeasy Micro Kit, and library preparation was conducted using the NEBNext® Small RNA Library Prep Set, followed by sequencing on an Illumina platform.
[0188] Bioinformatic analysis revealed that iPSC-EVs contained diverse populations of small noncoding RNAs, variously annotated as transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), piwi -interacting RNAs (piRNAs), microRNAs (miRNAs), and other small RNAs. Many of these are not full-length, consistent with the abundance of RNA fragments in EVs. The various RNA classes were of similar relative abundance in EV-1 and EV-2, with tRNAs being the most enriched (51.4% and 61.5%, respectively), followed by rRNAs, and smaller fractions of piRNAs and miRNAs (FIG. 5).
[0189] FIG. 5: Distribution of small RNA species in the EVs from two iPSC cell lines.
[0190] These data confirm that iPSC-EVs are actively loaded with a variety of small regulatory RNAs, consistent with their proposed role in cell-to-cell communication. The overlap in RNA profiles between two unrelated donors, one male and one female, suggests a conserved EV cargo spectrum and common mechanistic themes underlying iPSC-EV bioactivity. Small RNAs (such as miRNAs and piRNAs) may contribute to the antiinflammatory and cardioprotective effects of iPSC-EVs.Example 6
[0191] This non-limiting example shows characterization and evaluation of iPSC-derived EVs in vitro and in vivo.Culture of human-derived iPSCs and collection of iPSC-EVs by ultracentrifugation
[0192] iPSCs are cultured in 5% CO2 at 37°C in T175 flasks pre-coated with human laminin-521 substrate (STEMCELL Technologies). mTeSR Plus culture medium (STEMCELL Technologies) is used and changed routinely until -70% confluence. Due to its serum-free nature (no serum-EV contamination), conditioned media is collected every 48 hours by aspirating the regular culture medium and stored at -80°C until EV isolation. Then, fresh or thawed conditioned media is at first centrifuged at 2,000 g for 10 minutes to remove dead cells and then the supernatant is centrifuged at 10,000 g for 30 minutes to remove debris and apoptotic bodies. The resultant second supernatant is filtered through a 0.22 pm membrane to remove large vesicles and then is centrifuged at 100,000 g for 70 minutes at 4°C to pellet the final EV product.Characterization of iPSC-EVs for size, morphology, and surface markers
[0193] The term EVs refers to all extracellular lipid bilayer vesicles. Among them, exosomes (-100 nm in diameter) are derived from multivesicular bodies and enriched in RNA cargo. Many stem cell-derived therapeutics are recognized to act, at least partially, through paracrine signaling via EVs. Although their bioactivity is often attributed to exosomes, the general term EVs is used to reflect the heterogeneous nature of the isolates. Serum-free media conditioned from iPSCs contain abundant EVs, many of which are exosomes as demonstrated by particle size and antigenic profiling.
[0194] iPSC-EVs are diluted 1 : 1000 and analyzed by NTA (Nanosight, Malvern) for size distribution. Fresh iPSC-EV samples are imaged using cryo-transmission electron microscopy. Then the EV identity is confirmed by immunoblotting for specific EV markers including CD63, Alix, CD81, and TSG101. The EV-depleted media serves as a negative control, and Calnexin (an ER protein not typically found in EVs) is used as a negative marker to confirm purity.Isolation of bone marrow-derived macrophages from human PBMCs and evaluation of iPSC-EVs in an in vitro macrophage model
[0195] Human peripheral blood monocytes is cultured in RPMI 1640 Medium with 10% FBS, and human M-CSF (Invitrogen) to create macrophages and the media was changedevery 2-3 days until day 7 to yield and isolate human BMDMs. On day 7, macrophages are activated by exposure to LPS for 1 hour, followed by treatment with test agents. The iPSC-EVs are evaluated in the macrophages model by adding the iPSC-EVs to the culture medium at a ratio of 1:100 (cells: EVs) after the LPS activation. Mice are randomized into eight experimental groups: Sham control (PBS), Vehicle control (LPS), EV-1 treatment (LPS + EV-1), EV-2 treatment (LPS + EV-2), EV-3 treatment (LPS + EV-3), EV-4 treatment (LPS + EV-4), EV-5 treatment (LPS + EV-5), EV-6 treatment (LPS + EV-6). Six replicates are performed per group. Twenty-four hours after treatment, RNA (n=3, biological replicates) and protein (n=3, biological replicates) are extracted for qPCR and western blotting to assess M1 / M2 macrophage markers (e.g., IL-6, CD206).Evaluation of iPSC-EVs in mice with MI for short-term efficacy.
[0196] To establish the mouse I / R model, male and female C57BL / 6 mice (8-10 weeks old) are housed in a pathogen-free facility and under general anesthesia, thoracotomy is performed at the fourth intercostal space, and the left coronary artery is ligated with 7-0 silk suture for 45 minutes, followed by reperfusion. Then twenty minutes post-reperfusion, mice receive a retro-orbital injection (targeting the venous plexus behind the eye) of either vehicle (PBS), EV-1 (2 x 1010particles in 100 pL PBS), EV-2 (2 x 1O10particles in 100 pL PBS), EV-3 (2 x 1010particles in 100 pL PBS), EV-4 (2 x 1010particles in 100 pL PBS), EV-5 (2 x 1010particles in 100 pL PBS), EV-6 (2 x 1010particles in 100 pL PBS). Two days post-MI, mice are euthanized, and 10% KC1 is injected into the left ventricle (LV) to arrest the heart in diastole. Hearts are harvested, washed in PBS, and sectioned into 1 mm slices to be stained with 1% TTC (Sigma-Aldrich) for 30 minutes at 37°C and imaged. Then, sections are imaged and weighed. The infarcted zones (white) are delineated from viable tissue (red) and analysed (ImageJ software). Infarct mass is calculated in the tissue sections according to the following formula: (infarct area / total area) / weight (mg). Then blood is collected by cardiac puncture at endpoint using serum tubes without anticoagulant to perform the Cardiac Troponin I ELISA assay. After 30-60 minutes of clotting at room temperature, samples are centrifuged at 3,000 g for 10 minutes at 4°C and the serum is collected and stored at -80°C for analysis. Cardiac Tnl is quantified using the Mouse Cardiac Troponin I ELISA Kit (Life Diagnostics) per manufacturer’s instructions. To assess cardiac inflammation, the heart tissues are embedded in optimal cutting temperature (OCT) compound and frozen at -80°C for sectioning. Serialsections of the heart are cut at the mid-papillary level in the transverse plane measuring between 5 and 6 pm using a cryostat (CM3050S, Leica) and adhered to superfrost microscope slides. Immunostaining is performed with standard protocols for primary antibody of CD68, CD206, iNOS and more inflammatory markers related to macrophage activities.
[0197] iPSC-EVs are isolated from the donor lines, with consistent physical characteristics including appropriate size (-150 nm) and expression of canonical EV surface markers. In vitro, the iPSC-EVs attenuate macrophage activation, reducing pro-inflammatory markers and increasing M2-associated genes. In vivo, iPSC-EVs improve cardiac protection in the MI model. Dosing can be increased or intramyocardial injection can be used to enhance delivery of the iPSC-EVs.Example 7
[0198] This non-limiting example shows increased macrophages in the heart following iPSC-EV treatment in a model of MI.
[0199] A mouse model of MI was treated with iPSC-EV, as described in Example 6. A significantly higher number of CD68+and CD206+cells were found in the heart following EV treatment compared to controls, indicating a more prominent M2 macrophage phenotype in EV-treated hearts (FIGs. 6A-6B, FIGs. 7A-7B). There was no significant difference in iNOS+cells, a marker of Ml macrophages (FIGs. 7C-7D). The overall increased in macrophage number was confirmed histologically (FIG. 14).Example 8
[0200] This non-limiting example shows RNA cargo and potential mechanisms of action in iPSC-EVs by transcriptomic analysis.RNA sequencing and analysis of RNASeq data of iPSC-EVs and inert normal human dermal fibroblast (NHDF)-EVs
[0201] Total RNA, including small RNAs, is extracted from iPSC-EVs and NHDF-EVs using the Qiagen miRNeasy Micro Kit, following the manufacturer’s protocol. Samples are eluted in RNase-free water and stored at -80 °C. NHDF-EVs are isolated using the same protocol as described above for iPSC-EVs to ensure consistency. RNA yield and integrity are assessed using the Agilent Bioanalyzer and samples displaying enrichment in small RNA range and minimal degradation was selected for sequencing. Small RNA libraries are generated usingthe NEBNext® Small RNA Library Prep Set for Illumina (NEB, Cat# E7330S) and each library is indexed for multiplex sequencing and amplified by 12-15 PCR cycles. Libraries are sequenced as 50 bp single-end reads on an Illumina NovaSeq 6000 platform at the Cedars-Sinai Genomics Core, targeting a depth of 20 million reads per sample. Six independent iPSC-EV preparations from each donor are sequenced (n=6).Analysis of RNAseq data from iPSC-EVs and NHDF-EVs
[0202] A comparison of the small RNA profiles between iPSC-EVs and NHDF-EVs can identify differentially enriched RNA species. Such RNAs can be selectively loaded into iPSC-EVs and may serve as effectors of therapeutic benefit. This comparative approach enables elimination of non-specific cargo and identification of RNAs with functional significance.
[0203] 1) Read preprocessing and quality control. Raw fastq files are trimmed using CLC Genomics Workbench software to remove adapter sequences, and filtered for quality using FastQC. 2) Alignment to reference genome. Clean reads are aligned to the GRCh38 / hg38 human genome using STAR (v2.7) or Bowtie, depending on the RNA type. 3) Annotation and quantification. Reads are annotated using miRBase (miRNAs), piRNABank (piRNAs), GtRNAdb (tRNAs), and Ensembl (for IncRNAs and others). Then, gene-level quantification is performed using featureCounts. 4) Differential expression analysis. Normalization and statistical analysis is conducted using DESeq2 in R. The differentially enriched RNAs is defined as those with an adjusted p-value < 0.05 and log2 fold-change > 1.5.Comparative study of RNA species from iPSC-EVs and NHDF-EVs and screening of highly enriched RNAs
[0204] 1) Comparative analysis of small ncRNAs. RNAs with consistent enrichment across all replicates and at least 2-fold upregulation in iPSC-EVs vs. NHDF-EVs are considered for the comparative analysis of small ncRNA.Network enrichment and target identification for prioritized RNA candidates.
[0205] 1) Network-based enrichment analysis of RNA candidates. The top ranked small RNAs identified are subjected to network enrichment analysis using tools such as RNAInter, or STRING. These platforms are used to identify enriched subnetworks, including RNA-protein and RNA-pathway interactions, based on experimentally validated or high-confidence predicted associations. Then the bioinformatic tools such as TargetScan ortRFtarget is applied to predict downstream targets of individual RNA species and targets related to immune regulation, cytokine signaling, or tissue repair are prioritized based on relevance to EV-mediated bioactivity. The selected small RNAs are synthesized with a 3’ biotin tag and transfected into primary BMDMs. After 24 hours, cells are lysed and RNA-protein complexes are isolated using the Pierce™ Biotinylated Protein Interaction Pull-Down Kit (Thermo Fisher). Streptavidin magnetic beads capture the biotin-tagged RNA complexes, which are washed and eluted per the kit protocol. Pulled-down proteins are analyzed by mass spectrometry to identify RNA-binding proteins, while co-isolated RNAs (if present) are assessed by RT-qPCR or RNA-seq. Scrambled RNA probes and no-RNA controls are included to confirm specificity.
[0206] The RNA sequencing can reveal distinct enrichment of small noncoding RNAs in iPSC-EVs compared to NHDF-EVs, including miRNAs, piRNAs, and tRNA fragments implicated in inflammation and tissue repair. The network analysis highlights regulatory networks involved in macrophage polarization, cytokine signaling, and cardiac remodeling.Example 9
[0207] This non-limiting example shows a comparison of the overall composition of ncRNA between iPSC-EVs and NHDF-EVs.
[0208] The overall composition of small noncoding RNAs (ncRNAs) was compared between iPSC-EVs and NHDF-EVs according to Example 8. The overall composition of ncRNAs differed markedly between iPSC-EVs and NHDF-EVs (FIG. 8). iPSC-EVs showed a greater proportion of piRNAs and miRNAs, while NHDF-EVs were overwhelmingly dominated by tRNA-derived fragments (81.98%).
[0209] To identify candidate ncRNAs with translational potential, sequence-level analysis of raw small RNA reads in iPSC-EVs was performed, ranking individual sequences by their abundance, purposely ignoring RNA annotation. This analysis unexpectedly revealed that the ten most abundant raw sequences were not distinct entities, but instead shared extensive sequence overlap (FIG. 1 IF, FIG. 17). Notably, these overlapping sequences were homologous with putative piR-31068, which itself was the RNA species most enriched in iPSC-EVs relative to NHDF-EVs (FIG. 11F). Thus, surprisingly, both abundance-based ranking and comparative enrichment analysis independently converged on a shared RNAsequence motif that was highly represented in iPSC-EVs. Based on this convergence, the shared sequence motif was chosen as the focus for functional evaluation and designed four truncated RNA variants, R1-R4, spanning the overlapping core sequence for downstream screening (FIG. 11G).Example 10
[0210] This non-limiting example shows the comparison of RNA species from iPSC-EVs and NHDF-EVs and screening of highly enriched RNAs.
[0211] Only RNAs with consistent enrichment across all replicates and at least 2-fold upregulation in iPSC-EVs vs. NHDF-EVs were considered for the comparative analysis of small ncRNA. The piRNA family is the most significantly enriched class of small RNAs in iPSC-EVs compared to NHDF-EVs (FIG. 9). Comparative analysis of reads revealed that several piRNAs exhibited strong enrichment, with piR-31068 showing the highest logic fold change (6.83) (FIG. 10). Additional top-enriched piRNAs included piR-35413, piR-38952, piR-31092, and piR-61648 (FIG. 10).Example 11
[0212] This non-limiting example shows validation of the biological functions of key RNA candidates in iPSC-EVs.Evaluation of bioactivity of RNA molecules in a mouse model of MI,
[0213] 1) Establishment of the acute I / R mouse model and RNA delivery. Male and female C57BL / 6 mice (8-10 weeks old) undergo myocardial I / R surgery, as described in the examples above. The left coronary artery is ligated for 45 minutes followed by reperfusion to simulate clinical MI. Then synthetic small RNAs, selected from the examples above and synthesized by Integrated DNA Technologies (IDT), are complexed with DharmaFECT in vivo transfection reagent (Horizon Discovery) and delivered via retro-orbital injection at a dose of: 5mg / kg, 20 minutes post-reperfusion. The control groups includes vehicle (PBS) and scrambled RNA controls.
[0214] 2) Assessment of infarct size and cardiac injury. At 48 hours post-injection, mice are euthanized and hearts harvested. Cardiac infarct size is quantified using TTC staining on 1 mm heart slices. Additionally, blood is collected, and serum cTnl levels is measured usingELISA to assess myocardial injury. Each group can include sufficient biological replicates (e.g., at least 10 biological replicates) to allow statistical comparison of treatment efficacy.
[0215] Heart tissue is embedded in OCT and cut to 5 pm using a cryostat followed by immunostaining with standard protocols for primary antibody of CD68, CD206, iNOS and more inflammatory cytokines related to macrophage activities. qPCR is used to assess downstream gene expression changes in heart tissue to explore inflammatory and reparative signaling pathways influenced.Loss-of-function study for enriched RNA molecules in a mouse model of MI,
[0216] 1) Design and administration of RNA inhibitors. siRNA or RNA inhibitors targeting the top candidate RNAs are synthesized with appropriate chemical modifications for stability. Inhibitors are delivered intravenously (1-2 nmol) using DharmaFECT, immediately after artery ligation. 2) Generation of RNA-depleted iPSC-EVs. iPSCs are transfected with siRNAs or antisense gapmers targeting the candidate RNAs 48 hours prior to EV collection. Depletion efficiency is confirmed by qPCR of EV RNA. EVs are purified by ultracentrifugation and dosed as in Example 6. 3) In vivo administration and analysis. MI mice are treated with either standard iPSC-EVs, RNA-depleted EVs, or control (scrambled) EVs (n=10). Functional analysis is performed as described above.Molecular profiling of heart to reveal RNA-driven targets and downstream pathways
[0217] 1) RNA and protein isolation from heart tissue. Left ventricular tissues are dissected from the infarct border zone and homogenized and the RNA is extracted using TRIzol, and protein is extracted using RIPA buffer supplemented with protease inhibitors. Quantitative RT-PCR is performed to assess mRNA levels of pro-inflammatory (IL-6, Tnf), anti-inflammatory (Argl, IL-10), and reparative (Vegfa, Tgfjll) genes. Each reaction is performed in triplicate with normalization to Gapdh.
[0218] 3) Protein analysis. Western blotting and immunohistochemistry is performed for iNOS, CD206, IL-6, and collagen I for protein analysis. Densitometric quantification is used to compare expression levels across treatment groups.
[0219] 4) Combined analysis of phenotyping results and bioinformatic predictions. In vivo functional outcomes are integrated with the computational predictions generated in the above examples. Correlating the phenotypic improvement (e.g., ejection fraction, fibrosis) with molecular target expression can provide the mechanistic validation.
[0220] One or more ncRNA species can partially or fully recapitulate the cardioprotective effects of iPSC-EVs in the MI model, while inhibition or depletion of these RNAs can diminish therapeutic efficacy. These outcomes are correlated with reduced fibrosis, improved cardiac function, and modulation of key inflammatory markers.Example 12
[0221] This non-limiting example shows bioactivity of sncRNA identified in iPSC- EVs in a mouse model of MI.
[0222] Three putative RNA fragments were identified from iPSC-EVs as described in Examples 8-10 (FIG. 11A). These were tested in a mouse model of MI, as described in Example 11 according to the schematic in FIG. 1 IB. R2 and R3 significantly reduced infarct size compared to vehicle (FIGs. 11C-11D), while only R3 led to a significant reduction in serum cTnl levels (FIG. 1 IE). These data support the role of the RNA fragments in modulating acute injury responses.Screening of truncated RNA sequences for in vivo bioactivity
[0223] To test the in vivo bioactivity of each candidate ncRNA, MI was induced in mice. Each RNA was formulated with DharmaFECT, a transfection reagent that supports in vivo RNA delivery, and administered as a single retro-orbital injection 20 minutes after reperfusion. Animals receiving DharmaFECT alone served as vehicle controls. Among the four variants tested, R2 and R3 significantly reduced infarct size, measured 48 hours post-MI, compared with vehicle-treated mice (FIG. 11H and FIG. Ill), while R3 and R4 reduced circulating cTnl levels. Notably, only R3 significantly reduced both measures of cardiac injury (FIG. 11 J), providing mutually-reinforcing evidence of cardioprotective efficacy. Thus, R3 was chosen as the lead candidate for further optimization and mechanistic studies.mREXl is a 25-nt noncoding RNA with immunomodulatory activity
[0224] Given the unreliability of piRNA annotation in somatic cells, a BLAST search of the R3 sequence was performed against the human transcriptome. Surprisingly, the sequence perfectly aligned with internal segments of three human mRNAs (HES7, FCGR2A, LARP4B) (FIG. 15A and 15B). These 3 transcripts arise from unrelated genes on distinct chromosomes, a feature unprecedented amongst RNA fragments in EV cargo. Based on this sequence-level evidence and following the naming convention for EV-derived RNAs, R3 was designated as mREXl (messenger / ?NA-derived fragment from extracellular vesicles, #7)(FIG. 12A). Structural modeling predicts that the 25nt mREXl will adopt a stable secondary structure containing defined stem-loop domains and exposed loops (FIG. 12B).
[0225] Given that iPSC-EVs attenuate inflammatory responses in vivo and in vitro, it was hypothesized that specific RNA cargo elements within these vesicles may recapitulate the immunomodulatory effects. To determine the impact of mREXl on macrophage inflammatory responses, mouse BMDM was transfected with mREXl, alongside a scrambled RNA and vehicle controls, and applied the bacterial endotoxin LPS to stimulate an inflammatory response (FIG. 12C). The scrambled sequence Scr matched mREXl in length (25 nt) and nucleotide composition, but arranged in a randomized order (FIG. 12A). This design controls for potential confounding effects related to RNA length, nucleotide content, chemical synthesis, and delivery efficiency, thereby isolating the contribution of nucleotide sequence order to biological activity. Compared with Scr and vehicle groups, mREXl significantly reduced the transcript levels of IL-6 and TNF-a (FIG. 12D and FIG. 12E), indicating that the iPSC-EV-mined RNA oligonucleotide can modulate macrophage inflammatory responses. Such evidence was also provided by cytokine array analysis (FIG.16A-16C). Moreover, BMDM exposed to mREXl exhibited increased CD206 expression (FIG. 16D and 16E), consistent with a shift toward an anti-inflammatory phenotype. Collectively, these results establish mREXl as a novel RNA fragment with demonstrable bioactivity in macrophages. This capacity to modulate macrophage polarization is particularly relevant to MI, where inadequate M2-like responses can delay inflammation resolution and compromise tissue repair, promoting adverse remodeling.mREXl confers cardioprotection and promotes macrophage phenotypic remodeling in vivo
[0226] To assess the in vivo cardioprotective efficacy of mREXl, mice underwent ischemia / reperfusion (ER) and received intravenous injections of mREXl, Scr or vehicle 20 minutes post-MI (FIG. 12F). Forty-eight hours later, animals that had received mREXl exhibited marked reductions in infarct size (FIG. 12G and FIG. 12H) and plasma cTnl levels compared with either Scr or vehicle groups (FIG. 121). Thus, mREXl is cardioprotective, an effect that is not attributable to nonspecific RNA exposure or vehicle. Immunostaining of post-MI heart sections revealed a pronounced reduction in iNOS+macrophages following mREXl exposure (FIG. 12J), accompanied by a concomitant increase in CD206' macrophages, relative to both Scr and vehicle controls (FIG. 12K), such that mREXl promoted a shift toward areparative macrophage phenotype within the injured heart. Tt was also shown that mREXl decreased the number of CD68+macrophages relative to controls (FIG. 12L). Moreover, transcripts of TNF-a and TGF-0 were both significantly reduced in the mREXl group (FIG.12M and FIG. 12N), supporting that mREXl dampens post-MI inflammatory responses and may limit progression toward pathological fibrosis. Importantly, these in vivo findings were consistent with the in vitro macrophage data and provided a mechanistic link between immune modulation and tissue-level protection. Collectively, these results identify mREXl as a cardioprotective RNA oligonucleotide with robust anti-inflammatory activity, reflected (and possibly mediated) by immunomodulatory effects on macrophages.mREXl exerts macrophage-dependent cardioprotective activity and is effective via oral administration
[0227] To directly assess whether macrophages are required for the cardioprotective activity of mREXl, macrophages were depleted using clodronate liposomes, followed by I / R and post-MI RNA delivery (protocol depicted in FIG. 13 A). In macrophage-depleted animals, mREXl failed to reduce infarct size or plasma cTnl levels, in contrast to its robust protective effects in mice with intact macrophages (FIG. 13B-13D). Thus, macrophages are required for mREXl -induced cardioprotection. Accordingly, it was considered if mREXl might be orally bioavailable when delivered in a casein / chitosan (C2) formulation that works for other macrophage-active cardioprotective RNAs. To test this conjecture, mREXl, Scr or vehicle were formulated in C2 and administered by oral gavage to mice 20 minutes post-MI (FIG. 13E). 48 hours later, both infarct size and plasma cTnl levels were lower in mice that had received mREXl as compared to either Scr or vehicle (FIGs. 13F-13H), demonstrating cardioprotective efficacy via the oral route. Immunostaining of the post-MI heart showed reduced iNOS+(FIG. 131), and increased CD206+, macrophages colocalizing with CD68 (FIG.13J). Taken together, the loss-of-function macrophage depletion studies and the oral bioavailability support the hypothesis that mREXl exerts its benefits through macrophagedependent pathways. This macrophage-centric mode of action highlights mREXl ’s potential as an orally deliverable RNA therapeutic to mitigate acute myocardial injury.Discussion
[0228] Despite decades of intensive investigation, no drugs effectively limit cardiac injury when administered after reperfusion in acute MI. In contrast, cell-basedapproaches, particularly CDC therapy, can confer cardioprotection through paracrine mechanisms even when given post-MI. But cells or EVs are difficult to develop clinically: manufacturing biologies is highly complex and susceptible to multiple missteps, from tissue harvesting to potency assays, identity and release criteria. Stable, molecularly-defined therapeutic agents are highly desirable alternatives. Given that EVs and their RNA cargo are the principal mediators of benefit post-MI, it is logical to hunt for defined RNA molecules within EVs that may suffice to confer cardioprotection. By mining the RNA contents of therapeutic cell-derived EVs, several natural short ncRNAs with salutary effects are identified herein. Such natural unmodified ncRNAs may themselves be therapeutic candidates, or they can serve as bioinspiration for more stable, chemically-modified synthetic ncRNA drugs. Here this established strategy is extended beyond adult cardiac progenitor cells to human iPSCs, providing both conceptual and practical advances for iPSC-based regenerative medicine. iPSCs offer genuine regenerative potential, yet their direct clinical application in cardiac disease is constrained by arrhythmogenic risk, not to mention the aforementioned manufacturing-related complexities. These limitations have motivated the search for acellular, off-the-shelf alternatives capable of retaining therapeutic efficacy while eliminating the risks inherent to cell transplantation. iPSC-EVs hold some promise, as they recapitulate many of the regenerative benefits of iPSCs themselves, but, as with the parent cells, translation of iPSC-EVs is limited by challenges in scalable manufacturing, compositional heterogeneity, and regulatory complexity. Herein an approach is provided to overcome these barriers by dissecting iPSC-EV RNA cargo at sequence resolution to identify new cardioprotective molecules.
[0229] A key advance of this study described herein lies in the strategy used to prioritize functional RNA candidates from iPSC-EVs. While annotation-based enrichment analysis revealed a marked overrepresentation of putative piRNA-class sequences in iPSC-EVs relative to biologically inert NHDF-EVs, it was recognized that piRNA annotation remains controversial outside of the germline context and may obscure the true nature of the nucleic acids in question. To overcome this limitation, conventional annotation was complemented with direct raw sequence quantification, enabling identification of dominant sequence motifs independent of existing databases. This dual approach revealed a convergence between the most abundant raw sequences and annotated RNAs, highlighting a specific sequence space rather than an annotation label as the focal point for downstream screening.This strategy emphasizes sequence-driven prioritization, ignoring class-based assumptions. Using this approach, a 25-nt ncRNA, mREXl, was identified that exhibits robust cardioprotective activity in vivo. Importantly, mREXl recapitulated key biological features of iPSC-EVs, including modulation of post-MI inflammation.
[0230] Both in vitro and in vivo, mREXl shifted macrophage polarization away from a pro-inflammatory phenotype toward a reparative state, providing a mechanistic link between RNA exposure and tissue-level protection. Loss-of-function studies further demonstrated that macrophages are required for mREXl -mediated cardioprotection, as depletion of macrophages abolished its therapeutic effects. This finding is consistent with prior work on exomers TY1 and TY2, supporting a mechanism whereby small RNAs from regenerative cell EVs promote tissue repair through immunomodulation. Notably, the macrophage dependence of mREXl activity also enabled oral delivery, as macrophages can acquire RNAs from the gastrointestinal tract and traffic them systemically. The therapeutic efficacy observed with oral delivery further underscores the translational potential of mREXl and highlights a practical advantage of this therapeutic modality.
[0231] The present work establishes mREXl as a lead ncRNA therapeutic candidate and validates a generalizable discovery paradigm for translating iPSC regenerative biology into clinically available RNA drugs. Collectively, these results demonstrate that the CREDO strategy is not limited to CDCs but can be successfully applied to pluripotent stem cells. By extending this framework to iPSC-EVs, a rational path is provided to disentangle the regenerative potential of iPSCs from the risks associated with cell transplantation. Rather than viewing iPSC-EVs as therapeutics in themselves, these data support a model in which iPSC-EVs serve as discovery platforms for sequence-defined RNA drugs, with improved manufacturability, standardization, and regulatory tractability relative to the parent stem cells.Chemical modification of mREXl and screening
[0232] In this non-limiting example, point mutation screening of mREXl derivatives was performed.
[0233] The design of mREXl derivative sequences by point mutation is shown in FIG. 18A, where new SEQ ID NOs: 10-14 were prepared. The results of immunomodulatory efficacy tests in a macrophage model in vitro assessing IL-6 and TNF-alpha are shown in FIG.18B.
[0234] Next, assessment of cardioprotection provided by mREXl derivatives was performed. FIG. 19A shows a schematic of the mouse I / R study design, and FIG. 19B shows TTC staining of the infarct area of mouse hearts after treatment and control. Quantification of infarct size is shown in FIG. 19C, and cTNI level as measured by ELISA showing cardiac injury after treatment and control is shown in FIG. 19D.
[0235] Further screening of mREXl derivatives with chemical modifications was performed. The designs of mREXl derivative sequences with locked nucleic acid (SEQ ID NO: 15) and phosphorothioate linkages (SEQ ID NO: 16) are shown in FIG. 20A. FIG. 20B shows the results of qPCR on a macrophage model in vitro showing decreased IL-6 level in the group treated with the locked nucleic acid modified derivative.
[0236] Next, assessment of cardioprotection provided by mREXl derivatives with chemical modifications was performed. FIG. 21 A shows a comparison of the sequences for mREXl (SEQ ID NO: 1), and SEQ ID NOs: 11, 15, and 16, where the derivative sequences are designated “TM1”. FIG. 2 IB shows TTC staining of the infarct area of mouse hearts after TM1 treatment and control. Quantification of infarct size is shown in FIG. 21C, and cTNI level as measured by ELISA showing cardiac injury after TM1 treatment and control is shown in FIG. 2 ID.
[0237] Stability of mREXl derivatives was assessed next. A schematic of the study design is shown in FIG. 22A, where exonuclease RNase R is incubated with RNA derivatives and then tested by PCR. Stability of mREXl, TM1 exposed to increasing concentrations of RNase R is shown in FIG. 22B and 22C.
[0238] This experiment was followed by a mechanistic investigation of mREXl / TMl. FIG. 23 shows the results of RNA sequencing of macrophages after mREXl treatment, with the volcano plot showing differentially expressed genes in mREXl treated group versus vehicle treated group (control). FIG. 24A shows fold change of top genes in the treatment group vs vehicle control. Quantification of CPM reads of SLC7A11 counts from RNA-seq results in the mREXl group and vehicle group is shown in FIG. 24B, and qPCR results showing increased SLC7A11 transcriptional level in the mREXl vs vehicle group are shown in FIG. 24C. From this data, it was concluded that SLC7A1 l is a potential target of mREXl in macrophages.
Claims
WHAT TS CLAIMED IS:
1. A method of treating a condition associated with inflammation and / or fibrosis, comprising administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10) or a sequence having no more than 3 substitutions thereto, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is, or is about 25 nucleotides long, further optionally wherein the nucleotide sequence is 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).
2. The method of claim 1, comprising a cytosine at position 1 of SEQ ID NO: 10.
3. The method of claim 1, wherein the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is G or C (SEQ ID NO: 33), optionally wherein the isolated nucleic acid consists of or consists essentially of the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).
4. The method of claim 1, wherein the isolated nucleic acid comprises a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2), wherein K is G or U, or a sequence having no more than 3 substitutions thereto.
5. The method of claim 1, wherein the isolated nucleic acid does not comprise: 5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ IDN0:3).
6. The method of claim 1, wherein the isolated nucleic acid comprises at least one chemically modified nucleotide, optionally wherein the at least one chemically modified nucleotide comprises a backbone modification.
7. An extracellular vesicle (EV)-free method of treating a condition associated with inflammation and / or fibrosis, comprising administering to a subject in need of treating a condition associated with inflammation and / or fibrosis a composition comprising:a therapeutically effective amount of an isolated nucleic acid comprising a nucleotide sequence of a noncoding RNA (e.g., PlWI-interacting RNA (piRNA)) in EVs from induced pluripotent stem cells (iPSC-EVs), or a sequence having (i) no more than 3 substitutions thereto, and / or (ii) a truncation of no more than 10 nucleotides thereof, wherein the nucleic acid is RNA, and wherein the nucleic acid is at most 35 nucleotides long; anda pharmaceutically acceptable excipient,wherein the composition is an EV-free composition, optionally wherein the piRNA is enriched in the iPSC-EVs.
8. The method of claim 7, wherein the iPSC are human iPSC.
9. The method of claim 7, wherein the iPSC are peripheral blood mononuclear cell (PBMC)-derived iPSC.
10. The method of claim 7, wherein the nucleotide sequence is selected from:5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:3); 5’-GCCCGGCUAGCUCAGUCGGUAGAGCAUGAGAC-3’ (SEQ ID NO: 4);5’-GGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 5); 5’-AUUGGUGGUUCAGUGGUAGAAUUCUCGCCUG-3’ (SEQ ID NO: 6); or5’-UUGGUGGUUCAGUGGUAGAAUUCUCGCCUGCC-3’ (SEQ ID NO: 7).
11. The method of claim 7, wherein the isolated nucleic acid comprises a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10) or a sequence having no more than 3 substitutions thereto, optionally wherein the nucleotide sequence is 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).
12. The method of claim 7, wherein the isolated nucleic acid comprises a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2), wherein K is G or U, or a sequence having no more than 3 substitutions thereto.
13. The method of claim 7, wherein the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is G or C (SEQ ID NO: 33), optionally wherein the nucleic acid consists of or consists essentially of the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).
14. The method of claim 1, wherein the condition associated with inflammation and / or fibrosis comprises inflammation and / or fibrosis of the heart or skeletal muscle.
15. The method of claim 1, wherein the condition associated with inflammation and / or fibrosis comprises a symptom and / or sequelae of heart failure or myocardial infarction.
16. The method of claim 1, wherein the condition associated with inflammation and / or fibrosis comprises ischemic cardiac muscle injury.
17. The method of claim 1, comprising intravenously, intramuscularly, or intracardially administering the therapeutically effective amount of the nucleic acid to the subject.
18. A method of immunomodulation, comprising contacting an effective amount of an isolated nucleic acid comprising a nucleotide sequence of: 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10) with a population of macrophages, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is, or is about 25 nucleotides long, further optionally wherein the nucleotide sequence is 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1)19. The method of claim 18, wherein the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is G or C (SEQ ID NO: 33), optionally wherein the isolated nucleic acid consists of or consists essentially of the nucleotide sequence: 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).
20. The method of claim 18, wherein the isolated nucleic acid comprises a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2), wherein K is G or U, or a sequence having no more than 3 substitutions thereto.
21. The method of claim 18, wherein the isolated nucleic acid does not comprise: 5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:3).
22. The method of claim 18, wherein the contacting comprises administering to a subject in need of treating a condition associated with inflammation and / or fibrosis the effective amount of the isolated nucleic acid.
23. The method of claim 18, wherein the contacting is done in vitro.
24. The method of claim 18, wherein the macrophage is a human macrophage.
25. The method of claim 18, wherein contacting the effective amount of the isolated nucleic acid reduces expression of one or more pro-inflammatory cytokines in the population of macrophages, optionally wherein the one or more pro-inflammatory cytokines comprises one or more of: CD40, IL-6, or IL- 12.-SO-26. The method of claim 1, wherein the nucleic acid comprises at least one chemically modified nucleotide, optionally wherein the at least one chemically modified nucleotide is a locked nucleic acid (LNA) and / or wherein the nucleic acid comprises a phosphorothioate bond between at least one pair of nucleic acid residues that are adjacent each other in the nucleotide sequence.
27. The method of claim 26, wherein the at least one chemically modified nucleotide comprises a backbone modification.
28. The method of claim 27, wherein the backbone modification comprises a backbone sugar modification.
29. The method of claim 1, wherein the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is G or C (SEQ ID NO: 33), wherein at least one of positions 1, 3, 5, 21, 23, and 25 of SEQ ID NO: 33 comprises a chemically modified nucleotide, optionally wherein the chemically modified nucleotide is a locked nucleic acid (LNA).
30. The method of claim 29, wherein each of positions 1, 3, 5, 21, 23, and 25 of SEQ ID NO: 33 comprises a LNA, optionally wherein the nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 15), wherein each of positions 1, 3, 5, 21, 23, and 25 of SEQ ID NO: 15 comprises a LNA.
31. An isolated nucleic acid comprising a nucleotide sequence of: 5’-SGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 32), wherein S is G or C, wherein the nucleic acid is RNA, wherein the nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long, further optionally wherein the isolated nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1), 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11), or 5’-CGUGGUUCAGUGGUAGAAUUCUCGC-3 ’ (SEQ ID NO: 12).
32. An isolated nucleic acid comprising a nucleotide sequence at least 95% identical to 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10), wherein the nucleic acid is RNA, wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long, further optionally wherein the nucleotide sequence is at least 95% identical to 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).
33. The isolated nucleic acid of claim 32, comprising a cytosine at position 1 of SEQ ID NO: 10.
34. The isolated nucleic acid of claim 32, wherein the nucleotide sequence is at least 95% identical to 5’-GGUGGUUCAGUGGUAGAAUUCUCGS-3’, wherein S is G or C (SEQ ID NO: 33).
35. The isolated nucleic acid of claim 31, comprising a nucleotide sequence of: 5’-GCAUKGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:2), wherein K is G or U, or a sequence having no more than 3 substitutions thereto.
36. The isolated nucleic acid of claim 31, that does not comprise: 5’-AGCAUUGGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ IDN0:3).
37. The isolated nucleic acid of claim 31, wherein the nucleic acid comprises at least one chemically modified nucleotide, optionally wherein the at least one chemically modified nucleotide is a locked nucleic acid (LNA) and / or wherein the nucleic acid comprises a phosphorothioate bond between at least one pair of consecutive nucleic acid residues.
38. The isolated nucleic acid of claim 37, wherein the at least one chemically modified nucleotide comprises a backbone modification.
39. The isolated nucleic acid of claim 38, wherein the backbone modification comprises a backbone sugar modification.
40. The isolated nucleic acid of claim 37, wherein the nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11), wherein at least one of positions 1, 3, 5, 21, 23, and 25 of SEQ ID NO: 11 comprises a chemically modified nucleotide, optionally wherein the chemically modified nucleotide is a locked nucleic acid (LNA).
41. The isolated nucleic acid of claim 37, wherein the nucleic acid comprises 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 15), wherein each of positions 1, 3, 5, 21, 23, and 25 of SEQ ID NO: 15 comprises a LNA.
42. The isolated nucleic acid of claim 31, wherein the nucleic acid consists of or consists essentially of the nucleotide sequence: 5’- GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 1).
43. An isolated nucleic acid comprising one of the following nucleotide sequences, or a sequence at least 95% identical to:(a) 5’-GGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO:1), wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long;(b) 5’-GGUGGUUCAGUGGUAGAAUUCU-3’ (SEQ ID NO: 10), wherein the isolated nucleic acid is at most 27 nucleotides long, optionally wherein the nucleic acid is 22 nucleotides long;(c) 5’-GGUGGUUCAGUGGUAGAAUUCUCGG-3’ (SEQ ID NO: 11), wherein the isolated nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long; or(d) 5 -CGUGGUUCAGUGGUAGAAUUCUCGC-3’ (SEQ ID NO: 12), wherein the isolated nucleic acid is at most 35 nucleotides long, optionally wherein the nucleic acid is 25 nucleotides long.
44. The isolated nucleic acid of claim 43, comprising at least one chemically modified nucleotide, optionally wherein the chemically modified nucleotide comprises a locked nucleic acid (LNA) and / or wherein the nucleic acid comprises a phosphorothioate bond between at least one pair of consecutive nucleic acid residues.
45. The isolated nucleic acid of claim 44, comprising any one of SEQ ID NOs: 1, 11, and 12, wherein the nucleic acid is 25 nucleotides long, and wherein each of positions 1, 3, 5, 21, 23, and 25 of the nucleic acid sequence comprises the LNA.
46. A kit comprising:the isolated nucleic acid of claim 31; anda pharmaceutically acceptable excipient.
47. A method of identifying candidate therapeutic nucleic acids, comprising: obtaining sequencing data of a plurality of nucleic acids from therapeutic extracellular vesicles (EV);identifying a candidate therapeutic nucleic acid based on:(a) an enrichment analysis of the sequencing data that has been annotated relative to a reference sequencing data of a plurality of nucleic acids from non- therapeutic EV, wherein the reference sequencing data has been annotated, wherein the enrichment analysis identifies a first sequence motif that is enriched in the sequencing data; and(b) a sequence-based quantification of abundance of the sequencing data that has not been annotated, wherein the sequence-based quantification identifies a second sequence motif that is enriched in the sequencing data,wherein a sequence homology between the first sequence motif and the second sequence motif identifies a candidate therapeutic nucleic acid,optionally wherein the annotated sequencing data comprises annotation for one or more of piRNA, miRNA, and tRNA.
48. The method of claim 47, wherein the nucleic acids are RNA, optionally wherein the RNA are non-coding RNA.
49. The method of claim 47, wherein the therapeutic EV are derived from induced pluripotent stem cells (iPSC), optionally wherein the iPSC are human iPSC, further optionally wherein the iPSC are peripheral blood mononuclear cell (PBMC)-derived iPSC.
50. The method of claim 47, wherein the first sequence motif is comprised in one or more of the 100 most abundant sequences in the annotated sequencing data, and / or the second sequence motif is comprised in one or more of the 100 most abundant sequences in the un-annotated sequencing data.
51. The method of claim 47, comprising testing in vitro and / or in vivo a therapeutic effect of the identified candidate therapeutic nucleic acid comprising the first and second sequence motifs.
